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1. Introduction 
Cytokine signalling is initiated through ligand interaction with specific members of the 
cytokine receptor superfamily. The subsequent receptor oligomerization and conformational 
change result in activation of either an intrinsic kinase domain or receptor associated 
kinases, notably the Janus (JAK) family of cytoplasmic tyrosine kinases. The activated JAKs 
phosphorylate tyrosine residues in the receptor and subsequently downstream substrates, 
such as the signal transducers and activators of transcription (STAT) proteins. Once 
recruited to the receptor complex, STAT proteins are themselves phosphorylated on 
tyrosine, dimerize and translocate into the nucleus, where they activate the transcription of 
genes mediating cytokine-induced responses (Ortmann et al., 2000). Cytokines also activate 
other signaling cascades, such as the Ras/Mitogen-Activated Protein Kinase (MAPK) and 
the Phosphoinositide 3-kinase (PI3K)/Akt pathways. These cascades have been implicated 
in the proliferation, survival, and differentiation of several cell types in the haematopoietic 
system (Geest and Coffer, 2009; Leevers et al., 1999. However, all these signalling pathways 
require precise cellular control and their deregulation has been implicated in haematopoietic 
disorders, autoimmune and chronic inflammatory diseases and cancer, making it important 
to understand the mechanisms by which these cytokine-mediated signalling pathways are 
controlled (Schade et al., 2006; Khwaja, 2006). 
It is therefore not surprising that multiple levels of control have evolved to finely 
modulate the threshold, magnitude and specific responses elicited by cytokine 
stimulation. This regulation is achieved through both positive and negative mechanisms. 
The aim of the present chapter is to review the current advances in the regulation of 
haematopoiesis, with special interest on inhibitory pathways. Understanding how 
haematopoiesis is modulated is essential to provide useful information on its 
physiological functioning, the pathological origin of many related haematological 
disorders and to yield potential therapeutic targets. 
2. Regulation of cytokine signalling pathways: Role of adaptor proteins 
Cytokine binding to their receptors results in tyrosine autophosphorylation of the associated 
tyrosine kinase and of the receptor cytoplasmic domain at sites where specific signalling 
molecules can bind. In this way, the cytoplasmic domain of these cytokine receptors serves 
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to initially localize the signalling response to the plasma membrane. It is the combination of 
the signalling proteins that are recruited to the receptor that then determines the quality of 
the response that is generated. Indeed, the location of the proteins inside the cell and the 
kinetics of their activation are important features of signal-transduction pathways. How the 
signalling molecules are localized in the cell and how the strength and quality of the signal 
is regulated is an area of intense research, and increasing attention has focused on the so-
called adaptor proteins as key molecules controlling these more complex aspects of signal 
transduction. 
Adaptor proteins lack enzymatic activity or other direct effector function. Adaptors can be 
transmembrane proteins, reside in the cytoplasm under resting conditions and be recruited 
to the membrane upon activation, or be localized by specific interactions in intracellular 
compartments. Regardless of their cellular localization, they possess an array of binding 
sites and modules that allow them to mediate specific protein-protein and protein-lipid 
interactions. Examples of binding domains in adaptors include Src-homology 2 (SH2) and 
Phosphotyrosine-binding (PTB) domains that bind to phosphotyrosine motifs, SH3 domains 
that bind to proline-rich sequences and Pleckstrin homology (PH) domain that recognizes 
phospholipids (Pawson and Scott, 1996). With an assemblage of modules and binding 
sequences, a single adaptor can serve as a scaffold protein for the binding of multiple 
proteins into complexes, bringing in this way effectors into close proximity to their targets. 
However, the general ability of adaptor proteins to amplify or inhibit signalling, highly 
depends on their cell-specific expression and level, as well as on that of their binding 
partners, their location in the cell, the stability of the interactions between the adaptor and 
its targets and in certain conditions, on the basal kinase/phosphatase activity in the cell.  
Lastly, it should be noted that the domains and motifs found in adaptors are also frequently 
present in enzymatically active molecules, such as tyrosine phosphatases of the SH2-
containing phosphatase (SHP) family and the ubiquitin ligases Casitas B-cell lineage 
lymphoma (c-Cbl) proteins, where they can mediate true adaptor-like functions and also 
orchestrate signalling complex formation. 
3. Inhibitory adaptors in cytokine signalling regulation  
New insights into the biology of adaptor protein function have been possible with the use of 
a variety of biochemical, cellular and imaging techniques, as well as in vivo genetic 
approaches. All these techniques have helped establish that adaptor proteins can affect the 
thresholds and the dynamics of signalling reactions by coordinating positive and negative 
feedback signals. Over the years, the majority of investigations on cytokine signalling 
pathways have mainly focused on the mechanisms of cytokine-receptor activation, whereas 
our knowledge of negative regulation has been less explored. However, the most recent 
research has placed increasing emphasis on the mechanisms by which cytokine signals are 
attenuated or terminated. Indeed, stringent mechanisms of signal attenuation are essential 
for ensuring an appropriate, controlled cellular response following cytokine stimulation. 
One could imagine how the aberrant assembly of macromolecular active signalling 
complexes could lead to disease: excess positive signalling or insufficient negative signalling 
may lead to autoimmunity, chronic inflammation or malignant transformation, while excess 
negative signalling or insufficient positive signalling may lead to immunodeficiency or 
certain haematological disorders. 
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A number of mechanisms have been proposed to regulate the initiation, duration, 
magnitude and specificity of cytokine signalling at multiple levels: 1) receptor 
internalization and inhibition mediated by soluble receptor antagonists and/or specific 
inhibitors (such as the Lnk and Dok adaptor proteins); 2) tyrosine dephosphorylation of the 
receptor and signalling intermediates mediated by tyrosine phosphatases; 3) proteosomal 
degradation of signalling molecules mediated by the suppressors of cytokine signalling 
(SOCS) proteins and the Cbl E3 ubiquitin ligases proteins; and lastly 4) transcriptional 
suppression mediated by specific inhibitors such as the protein inhibitors of activated 
STATs (PIAS) proteins. In this section, we review what is currently known about the 
function and regulation of four families of inhibitory adaptor proteins that are key players 
in some of the regulatory mechanisms mentioned above. These families are the DOK, the 
Lnk/SH2B3, the Cbl and the SOCS proteins. We first discuss the adaptors without catalytic 
activity (DOK and Lnk), followed by those possessing an enzymatic function (Cbl and 
SOCS). The latter ones are also known as scaffold proteins; however we will refer to them as 
adaptors in hopes that this distinction provides a clear picture on the different properties of 
each.  
 
Fig. 1. Schematic representation of the domain structure of inhibitory adaptors 
3.1 The DOK family 
3.1.1 Structure and cell expression 
The Dok (Downstream Of Tyrosine Kinases) family of adaptor proteins consists of seven 
members, Dok 1 to Dok-7, that differ in the length of their C-terminal region. They are all 
characterized by an N-terminal PH domain, a central PTB domain and multiple SH2 and 
SH3 binding motifs in the C-terminal region (Figure 1). Dok-1 (p62dok), Dok-2 (p56dok-2, also 
called Dok-R, or FRIP) and Dok-3 (also called DokL) are preferentially expressed in the 
haematopoietic compartment, as well as co-expressed in haematopoietic progenitors 
(Carpino et al., 1997; Yamanashi et al., 1997; Di Cristofano et al., 1998; Lemay et al., 2000). 
All three Dok proteins are expressed in myeloid cells, but differ in their lymphoid lineage 
expression. While Dok-1 and Dok-2 are highly expressed in T cells, Dok-3 is little or not 
detected at all. In contrast, Dok-1 and Dok-3 are expressed in B cells, while Dok-2 is not 
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normally detected in these cells. Moreover, several studies have demonstrated that Dok-1 
and Dok-2 expression was up or down-regulated, respectively, by different signalling 
pathways in immune cells. Dok-1 expression was upregulated in response to the 
glucocorticoid dexamethasone in RBL-2H3 mast cells (Hiragun et al., 2005). By contrast, its 
expression was downregulated in bone marrow-derived macrophages in response to 
lipopolysaccharide (LPS) [Shinohara et al., 2005]. As for Dok-2, its expression increased in 
response to cytokines such as M-CSF, granulocyte–macrophage colony stimulating factor 
(GM-CSF), and interleukin-3 (IL-3) in NFS-60 myeloid leukemia cells, suggesting its 
implication in a negative feedback loop for the regulation of these cytokine pathways (Suzu 
et al., 2000). The other Dok proteins, Dok-4 (IRS5), Dok-5 (IRS6), Dok-6 and Dok-7 are 
mainly expressed in non-haematopoietic cells, notably in neural cells. However, Dok-4 was 
reported to function as negative regulator in human T cells (Favre et al., 2003). 
 
Dok protein Binding domain Binding partner Signalling Receptor 
Dok-1 PTB Abl  BCR 
  SHIP-1 FcRIIB 
  Dok-1, Dok-2 CD2 
  TCR idem 
 pY CD3 idem 
  p120RasGap BCR, CD2+CD28, FcRI 
  Abl, Lyn BCR  
  Nck FcRI  
  SHIP-1 FcRIIB, FcRI 
Dok-2 PTB SHIP-1 FcRIIB 
  Dok-1, Dok-2 CD2 
  TCRCD3 idem 
 pY p120RasGAP,Abl BCR 
  Nck TCR 
Dok-3 PTB SHIP-1, Abl FcRIIB 
  Dok-3 BCR 
 pY Grb2 BCR 
  SHIP-1 FcRIIB 
Table 1. Signalling partners bound to the different domains and motifs of Dok proteins 
3.1.2 Signalling partners 
The biological functions of the Dok proteins have been defined with the identification and 
functional analysis of their binding partners, as well as of their subcellular localization. Dok-
1 was the first member of this family identified as a tyrosine-phosphorylated 62 kDa 
substrate of both v-ABL and BCR-ABL and associated with p120RasGap, a negative 
regulator of Ras. Several studies have later shown that Dok-1/2/3 can be tyrosine 
phosphorylated by a variety of growth factors, cytokines and immuno receptors, providing 
multiple docking sites for SH2 and PTB-containing proteins such as Nck, SHP-1, SHIP-1 and 
p120RasGap (Table 1). The interaction between p120RasGap and Dok-1/2 has been the most 
extensively studied and the one likely responsible for the negative regulation of the Ras/Erk 
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pathway mediated by the Dok adaptors. It involves the SH2 domain of p120RasGap and its 
binding motifs present in the C-terminal moiety of Dok-1/2 (Songyang et al., 2001). In 
contrast, Dok-3 protein has no YxxP motifs and therefore is unable to associate with p120 
RasGap. However, it can negatively regulate Erk activation through its binding with Grb2 
(Honma et al., 2006). Fewer signalling molecules have been reported to associate with the 
PTB domain of Dok-1/2/3 (Table 1). Interestingly, these Dok proteins show homotypic and 
heterotypic (for Dok-1/2) oligomerization that is dependent on their tyrosine 
phosphorylation and PTB domains. Moreover, this oligomerization appears crucial to their 
function, at least for Dok-1/2 (Boulay et al., 2005). Instead, the functional relevance of Dok-3 
oligomerization is not yet clear (Stork et al., 2007). The presence of a PH domain in the 
structure of Dok proteins suggests an important role for this domain in the localization or 
translocation of the Dok adaptors to cellular membranes. Indeed, it seems that Dok-1 and 
PI3K activity are required for the recruitment of the adaptor to the membrane and its 
negative effect on PDGF-mediated ERK activation. Furthermore, Dok-1/2 PH domain can 
bind tightly to PI(5)P and modulate the negative function and tyrosine phosphorylation of 
the adaptors in T-cells (Guittard et al., 2009). Conversely, the PH domain of Dok-3 is 
important for its localization to the membrane in B cells (Stork et al., 2007). 
3.1.3 Signalling pathways in immune cells 
Studies with Dok-1/2/3 deficient mice and/or cells have helped demonstrate the 
physiological importance of these inhibitory adaptors to the function and development of 
immune cells. Using Dok-1-deficient splenic B cells, Yamanashi et al. demonstrated a 
negative role of Dok-1 in antigen receptor-mediated signalling through suppression of 
MAPK activity and cell proliferation (Yamanashi et al., 2000). Moreover, co-cross-linking of 
the B-cell receptor (BCR) and FcRIIB receptor induces the tyrosine phosphorylation of Dok-
1 and its subsequent association with RasGap (Vuica et al., 1997). In FcRIIB signalling, Dok-
1 is recruited to the receptor complex at the membrane via SHIP, and in this way, 
contributes to the negative regulation of the Erk pathway [Figure 2.] (Tamir et al., 2000). On 
the other hand, Dok-3 is also expressed in B cells and therefore, one can expect a functional 
redundancy between Dok-1/3 in these cells. Indeed, it was reported that Dok-3 can function 
as a negative regulator of BCR-mediated responses (Ng et al., 2007). Furthermore, both Dok-
1 and Dok-3 were shown to be phosphorylated by Lyn kinase after stimulation of the BCR, 
suggesting that Lyn can activate these Dok proteins to then function as negative regulators 
in B cells (Yamanashi et al., 2000; Stork et al., 2007). However, B cells from Dok-3-deficient 
mice exhibited augmented proliferation and Ca2+ influx upon BCR stimulation (Ng et al., 
2007), while these responses are not observed in the absence of Dok-1 (Yamanashi et al., 
2000). These phenotypic differences could be attributed to Dok-1, but not Dok-3, recruiting 
p120RasGAP, which can inhibit Ras/Erk signalling; by contrast, Dok-3, but not Dok-1, can 
recruit Grb2, which can then inhibit Ca2+ signalling in B cells. 
Dok-1 and Dok-2 adaptor proteins have been also shown to play a role in the maintenance 
of T-cell homeostasis. In some cell line systems, Dok-1 is phosphorylated by Lck kinase and 
associates with RasGap upon CD2 and CD28 stimulation, but not CD3-TCR engagement, 
indicating a possible role of Dok-1 in T cell signalling (Nemorin & Duplay, 2000). 
Furthermore, overexpression of Dok-2 results in a dramatic reduction in both thymocytes 
and splenic T-cell numbers, suggesting a negative role of Dok-2 in T-cell development 
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(Gugasyan et al., 2002). Although the molecular mechanisms underlying the Dok-mediated 
inhibition are unclear, Dok proteins can bind to the ITAM motifs of TCR and CD3 through 
their PTB domain. As these ITAMs are essential for the binding and activation of ZAP-70, 
interference between the Dok proteins and ZAP-70 might occur through their binding to the 
ITAMs (Figure 2). Recently, Nunès and colleagues reported that the PH domain of Dok-1 
and Dok-2 is necessary for the tyrosine phosphorylation of these Dok proteins and their 
negative functions in T cells (Guittard et al., 2009). These results demonstrate the functional 
relevance of the membrane localization of the Dok adaptors. 
 
Fig. 2. Dok-mediated signalling pathways in immune cells 
Unlike lymphoid cells, myeloid cells express all the immune cell Dok proteins. However, the 
loss of Dok-1 and Dok-2 causes mainly neoplastic abnormalities in myeloid cells, suggesting 
an important role in immune and cytokine receptor signalling in these cells. Analysis of Dok-
1 and Dok-2 deficient myeloid cells showed enhanced proliferation and survival in response 
to Stem Cell Factor (SCF), IL-3, macrophage-colony stimulating factor (M-CSF), and 
granulocyte-monocyte-colony stimulating factor (GM-CSF), which are cytokines crucial for 
myelopoiesis. These findings indicate that Dok-1 and Dok-2 act as key negative regulators of 
signalling downstream of these cytokine receptors. Indeed, the activation of Erk and Akt in 
macrophages deficient for Dok-1 and Dok-2 was strongly augmented compared with that in 
wild type controls upon M-CSF receptor stimulation, confirming the role of Dok adaptors as 
negative regulators for these pathways. On the other hand, the role of Dok-1 and Dok-2 was 
examined in innate immune signalling in macrophages. Stimulation of macrophages by LPS 
induces rapid tyrosine phosphorylation of Dok-1 and Dok-2, suggesting the involvement of 
these adaptors in TLR4 signalling (Shinohara et al., 2005). In addition, the stimulation of 
Dok-1 or Dok-2-deficient macrophages promoted the activation of Erk and hyperproduction 
of TNF- and nitric oxide, two major signalling mediators of innate immunity, indicating 
that the Dok proteins are key negative regulators of TLR4 signalling in macrophages. The 
Dok adaptors are also expressed in mast cells where they have been shown to interact 
exclusively with negative regulators of FcεRI signalling. FcεRI stimulation leads to the 
tyrosine phosphorylation of only Dok-1 and Dok-2. Nevertheless, Dok-3 associates with 
tyrosine-phosphorylated proteins upon FcεRI stimulation, implicating a yet undefined 
function for this adaptor protein downstream of the receptor (Abramson et al., 2003). A 
complex of Dok-1, RasGAP, and SHIP-1, similar to the one described in B cells after co-
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aggregation of the BCR with FcγRIIB, was also described in mast cells after FcεRI and 
FcγRIIB co-aggregation (Ott et al., 2002). Moreover, Dok-1 has also been involved 
downstream of activating receptors, like FcεRI, by associating with and negatively 
regulating signals without the involvement of inhibitory receptors (Ott et al., 2002; 
Abramson et al., 2003). However, Dok-1-deficiency did not affect mast cell activation, 
suggesting a possible functional redundancy among the different isoforms expressed in 
these cells. 
Recently, two groups have reported the expression and function of the Dok proteins in 
human platelets.  Using a proteomic approach in these cells, it was shown that Dok proteins 
are tyrosine phosphorylated downstream of main platelet activation receptors (Garcia et al., 
2004; Hughan et al., 2007; Senis et al., 2009). Tyrosine phosphorylation of Dok-1 and Dok-3 
was primarily Src kinase-independent downstream of the integrin pathway, whereas it was 
Src-dependent downstream of glycoprotein VI (GPVI) pathway. Both proteins interact in an 
inducible-fashion with Grb-2 and SHIP-1 in fibrinogen-spread platelets, suggesting that the 
formation of a multi-molecular negative signalling complex may be a mechanism of down-
regulating IIb3 outside-in signalling. 
3.2 The Lnk/SH2B family 
3.2.1 Structure, origin and cell expression 
The Lnk (or SH2B) family of adaptor proteins is composed of 3 members, SH2-B [also 
known as PSM (proline-rich, PH and SH2 domain-containing signalling mediator) or 
SH2B1], APS (for Adaptor protein with PH and SH2 domain, also known as SH2B2) and 
Lnk (SH2B3). They all possess a dimerization (DD) domain and proline-rich motifs at the N-
terminus, followed by a PH and SH2 domains, and several potential tyrosine 
phosphorylation sites, notably a conserved tyrosine residue at the C-terminus [Figure 
1](Rudd, 2001). The SH2B1 gene encodes four isoforms (, , , ) resulting from alternative 
mRNA splicing at their 3’ terminus giving rise to proteins differing at their C-terminus 
(Nelms et al., 1999). SH2-B and  isoforms were originally cloned from yeast tribrid and 
two-hybrid systems screening, respectively, using different proteins as baits (Osborne et al., 
1995; Riedel et al, 1997; Rui et al., 1997). Despite its initial identification in immune cells, 
SH2-B isoforms are mainly expressed and functional, as shown by gene inactivation in mice, 
in non-haematopoietic tissues. The APS/SH2B2 gene encodes for two isoforms, SH2B2 and 
recently identified SH2B2 (Li et al., 2007). The APS protein was also identified in a two-
hybrid system screening of human B cells or adipocytes (Yokouchi et al., 1997; Moodie et al., 
1999). Like SH2-B, APS adaptor protein is also highly expressed in non-haematopoietic 
tissues. However, it is also expressed in haematopoietic cells, notably in mature B and mast 
cells. As for Lnk, it has only one form in mammalians and one invertebrate orthologue in 
Drosophila melanogaster (D-Lnk) to date (Werz et al., 2009). The Lnk adaptor protein was the 
first member of this family identified (Huang et al., 1995; Takaki et al., 1997). However, it 
was later found that the Lnk protein was much larger than initially reported (Li et al., 2000; 
Takaki et al., 2000; Velazquez et al., 2002). In contrast to SH2-B and APS, Lnk is mainly 
expressed in haematopoietic cells, notably in haematopoietic stem cells (HSC), and 
haematopoietic (lymphoid and myeloid) progenitors. Moreover, Lnk expression is up-
regulated by certain cytokines important for the development and function of these 
haematopoietic cells, such as SCF, thrombopoietin [TPO], and erythropoietin [EPO] (Kent et 
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al., 2008; Buza-Vidas et al., 2006; Gerry et al., 2009a, 2009b; Baran-Marszak et al., 2010). 
Interestingly, Lnk is also highly expressed in endothelial cells and its expression is also 
induced by Tumor Necrosis Factor (TNF)- (Fitau et al., 2006; Kwon et al., 2009). These 
findings suggest the implication of Lnk adaptor in a negative feedback loop for the 
regulation of these cytokine pathways. 
3.2.2 Signalling partners 
Over the last years, much effort has gone into understanding the role of the Lnk family as 
signalling regulators through the identification of the molecules binding to their different 
functional domains and motifs, as well as their signalling pathways (Table. 2). The SH2 
domain of the Lnk adaptor proteins is implicated in most of the key molecular interactions 
between the adaptors and their partners/effectors and their biological functions. The fist 
identified binding partner of the Lnk protein was the SCF receptor, Kit. The primary Kit-
binding site for Lnk SH2 domain has been identified as phosphotyrosine 567 (pTyr567), 
which resides in the juxtamembrane region of the receptor (Simon et al., 2008; Gueller et al., 
2008). Similarly, the SH2 domain of APS was reported to bind to Y568 and Y936 in the 
human c-Kit receptor (Wollberg et al., 2003). Interestingly, this region of Kit contains critical 
tyrosine (Y) residues (Y567/69) for the recruitment of different regulatory signalling 
molecules (Chan et al., 2003). In this system, a proposed mode of action of Lnk is that once 
bound to the juxtamembrane region of Kit, it will then block the association of activators 
with the receptor, resulting in down-regulation of SCF-mediated pathways. Indeed, 
expression of an SH2-inactive Lnk protein abolishes Lnk-mediated negative regulation of 
SCF-induced cell proliferation and migration (Simon et al., 2008). Lnk has been also reported 
to bind through its SH2 domain to other tyrosine kinase receptors, such as the PDGFR and 
the M-CSF receptor (c-Fms); however the physiological implication of these associations is 
not yet clear (Gueller et al., 2010, 2011). 
The JAK2 tyrosine kinase was the first characterized binding partner of SH2-B and APS, and 
subsequently of Lnk. This association results in activation of the kinase in the case of SH2-B 
and APS or in its inhibition when bound to Lnk. Different biochemical studies have shown 
that the interaction of the SH2 domains of SH2-B and APS occurs preferentially with kinase-
active, tyrosyl phosphorylated JAK2 (Rui et al., 1997). The primary JAK2-binding site for the 
SH2 domain of the Lnk family has been identified as pTyr813, which resides within the 
regulatory JH2 pseudokinase domain of JAK2 (Kurzer et al., 2004, 2006). Crystallographic 
studies have demonstrated that the SH2 domain of APS dimerizes when binding to the 
insulin receptor, whereas the SH2 domain of SH2-B, binds JAK2 as a monomer (Hu et al., 
2003; Hu & Hubbard, 2006). Less is known on how the Lnk SH2 domain binds JAK2. 
However, it has been shown that Lnk is capable of binding JAK2 wild-type form, as well as 
the constitutive active JAK2-V617F form present in myeloproliferative neoplasms (Bersenev 
et al., 2008; Gery et al., 2009; Baran-Marszak et al., 2010). In addition to the SH2-dependent 
interaction of the Lnk adaptor family with pTyr813 in JAK2, there appears to be one low-
affinity interaction involving amino acids outside the SH2 domain in the adaptors and 
inactive JAK2 that might prevent abnormal activation of the kinase. (Rui et al., 2000; Kurzer 
et al., 2006; Baran-Marzak et al., 2010).  
The N-terminal region of the Lnk adaptor family contains a dimerization domain whose 
crystal structure has revealed a “phenylalanine zipper” motif. This domain mediates SH2-B  
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Lnk proteins  Binding domain Binding partner Cells System  
Lnk N-term Lnk COS 
 Inter PH-SH2 ABP-280 COS, T cells (TCR) 
 SH2 Kit Mast (SCF) 
  JAK2 Myeloid (EPO, TPO) 
  c-Fms Myeloid (M-CSF) 
  PDGFR COS (PDGF) 
APS N-term APS, SH2B HEK293, CHO (In) 
 PH Vav3 NIH3T3 
 SH2 Kit Mast (SCF) 
  JAK2 Myeloid (GH) 
  IR Adipocyte (In) 
 pY618 Cbl Adipocyte (In) 
SH2B N-term SH2B, APS CHO (In), COS 
  Rac CHO, COS (GH) 
 SH2 JAK2 Myeloid (GH) 
  GHR, IR Adipocyte (GH, In) 
GHR, growth hormone receptor; IR, insulin receptor; In, insulin 
Table 2. Signalling partners bound to the different domains and motifs of Lnk proteins. 
and APS homo and heterodimerization that appears crucial to their function (Dhe-Paganon 
et al., 2004). Instead, Lnk homodimerization has only been shown in an over-expressed 
system (Takizawa et al., 2006) and therefore, its functional relevance is not yet clear.  
The presence of a PH domain in the structure of Lnk proteins suggests an important role for 
this domain in the localization or translocation of these adaptor proteins to cellular 
membranes. Indeed, previous reports showed that Lnk PH mutants (W191A or W270A) 
proteins moderately affected Lnk modulation of TPO-, EPO- or SCF-dependent biological 
responses (Tong & Lodish, 2004; Tong et al., 2005; Simon et al., 2008). Moreover, the Lnk PH 
domain seemed to display moderate affinity and little specificity to phosphoinositides in 
vitro. It is therefore possible that the Lnk PH domain may down-regulate membrane 
targeting of Lnk in the absence of docking site for the SH2 domain and increase binding 
stability to membrane receptors when the SH2 domain is engaged.  
Association of Lnk, APS and SH2-B with growth factor, cytokine receptors or the JAK2 
kinase allows phosphorylation of these adaptors and their proper localization at the 
signalling complex. The conserved C-terminal tyrosine residue present in all members of 
this family has been shown to be a main site for phosphorylation upon growth factor or 
cytokine stimulation. In Lnk, this residue, Y536, was suggested to be phosphorylated upon 
SCF stimulation in a mast cell line (Takaki et al., 2002). However, an Lnk form mutated at 
this tyrosine still gets phosphorylated upon Kit activation in primary mast cells (Simon et 
al., 2008). This result suggested that Lnk could be phosphorylated at sites other than Y536. 
Indeed, a similar result was reported with human Lnk mutated at this residue (Li et al., 
2000). On the other hand, the biological relevance of Lnk Y536 seems to depend on the 
signalling pathway analyzed. Lnk Y536 is dispensable for lymphoid development, TPO- or 
SCF-dependent signalling pathways, but it might play a regulatory role in IL3- and EPO-
mediated proliferation (Takaki et al., 2003; Tong & Lodish, 2004; Simon et al., 2008). 
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However, no Lnk binding partners for this site has so far been identified. In contrast, APS C-
terminal tyrosine, Y618, has been shown to get phosphorylated by activated growth factor 
(IR), cytokine (EPO) and immune (BCR) receptors and then serve as binding site for the Cbl 
protein (Moodie et al., 1999; Yokouchi et al., 1997; Wakioka et al., 1999). The APS/Cbl 
association plays an important role in down-regulation of IR signalling (Kishi et al., 2007). 
Other binding proteins have been identified that associate with other regions of Lnk, APS 
and SH2-B that are involved in actin regulation. In particular, an amino acid sequence in the 
N-terminal region of SH2-B has been shown to bind to Rac, a mayor actin regulating 
protein, while a similar sequence in APS can associate with Vav3, a guanine nucleotide 
exchange factor for Rac (Diakonova et al., 2002; Yabana and Shibuya, 2002). Lnk was 
demonstrated to associate with the actin binding protein ABP-280 via a sequence between 
the PH and SH2 domains of human Lnk in Jurkat T cells (He et al., 2000).  These findings 
suggest a role for the Lnk family members in the regulation of actin cytoskeleton and cell 
motility. 
3.2.3 Signalling pathways in haematopoietic cells 
The initial in vitro biochemical analysis was done on SH2-B and APS and showed that these 
adaptors were phosphorylated and became positive mediators of receptor and protein 
tyrosine kinases cascades. However, APS can also function as negative regulator in the BCR 
and JAK2 signalling pathways (Yokouchi et al., 1997; Wakioka et al., 1999). Conversely, Lnk 
is considered as a negative regulator of growth factor and cytokine receptor-induced 
proliferation and migration (Takaki et al., 2000, 2002; Velazquez et al., 2002; Tong & Lodish, 
2004; Tong et al., 2005; Fitau et al., 2006; Simon et al., 2008; Gueller et al., 2010, 2011). 
Nonetheless, Lnk seems to play a positive role in mouse platelets for the stabilization of 
thrombus through the integrin IIb3 outside-in signalling and in human vascular 
endothelial cells via the PI3K/Akt pathway activated by TNF- (Takizawa et al., 2010; Fitau 
et al., 2006).  Together with data on in vivo ablation of these adaptors, these findings 
demonstrate that these adaptor proteins can function as positive and/or negative regulators 
depending on their cell expression and on the growth factor or cytokine receptor–mediated 
pathway. 
The generation of mice and cell lines deficient for members of this family has confirmed Lnk 
and APS, but not SH2-B, specific function in the haematopoietic system, while establishing 
SH2-B implication in other tissues. As stated before, Lnk is highly expressed in HSC, so as 
expected, Lnk-/--derived HSC show an increased capacity to proliferate and to self-renew 
together with an increase in the quiescent fraction. These effects on HSC homeostasis are due 
to abnormal TPO signalling in these cells, that results from an enhanced TPO hypersensibility, 
increased TPO-dependent activation of Akt, STAT5 and down-regulation of p38MAPK (Ema 
et al., 2005; Buza-Vidas et al., 2006; Seita et al., 2007; Bersenev et al., 2008). These findings 
therefore confirm that Lnk controls TPO-induced self-renewal, quiescence and proliferation of 
HSC. Moreover, Lnk deficiency enhances the ability of HSC and haematopoietic progenitors to 
reconstitute the haematopoietic system in irradiated hosts. Indeed, transient inhibition of 
endogenous Lnk significantly increased the repopulating capacity of the transduced cells and 
thereby, engraftment (Takizawa et al., 2006). Moreover, analysis of Lnk-/--derived 
haematopoietic progenitors show an hypersensibility to several cytokines resulting in 
sustained MAPK, JAK/STAT activation and cell proliferation (Takaki et al., 2000; Velazquez et 
al., 2002; Tong, 2005; Takizawa et al., 2008). 
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Lnk-deficient mice have also revealed an essential role for Lnk in B cell lymphopoiesis with 
the selective expansion of pro-/pre-B and immature B cells in bone marrow and spleen. This 
abnormal proliferation is partly due to hypersensitivity to SCF and IL-7 (Takaki et al., 2000; 
Velazquez et al., 2002). Alternatively, Lnk over-expression in transgenic mice show 
impaired B production in an Lnk dose-dependent manner confirming the negative control 
mediated by this adaptor in B-lineage cell production (Takaki et al., 2003). However, no 
evident effect on mature B cells was observed in the absence of Lnk, suggesting either a lack 
of role for Lnk in this population or a functional compensation by APS in these cells. APS 
has also been shown to play a role in B cell development and function. Ablation of APS in 
mice caused an increase in B-1 cell number and an enhanced humoral immune response 
against a thymus-independent type 2 antigen, suggesting a role for APS in mature B cell 
proliferation (Iseki et al., 2004). Accordingly, APS transgenic mice showed reduced numbers 
of peritoneal B-1 and splenic B cells and impaired BCR-induced proliferation of mature B 
cells (Iseki et al., 2005). In these cells, APS co-localized with pre-activated capped BCR 
complexes and filamentous actin, indicating a negative regulatory role for APS in BCR 
signalling and actin reorganization. 
Lnk has been also shown to control erythropoiesis and megakaryopoiesis. Studies on primary 
Lnk-/- erythrocytes and megakaryocytes indicate an abnormal proliferation due to the absence 
of negative regulation of EPO and TPO signalling pathways (Figure 3). Indeed, Lnk, through 
its SH2 domain, negatively modulates MPL, and EPO receptor (EPOR) signalling by 
attenuating three major signalling pathways: JAK2/STAT, MAPK and Akt (Tong et al., 2005; 
Tong & Lodish, 2004). Moreover, Lnk is capable of binding and regulating MPL-W515L and 
JAK2-V617F, the mutated forms expressed in Myeloproliferative Neoplasms [MPN] (Gery et 
al., 2007, 2009; Bersenev et al., 2008; Baran-Marszak et al., 2010). In addition, Lnk also regulates 
thrombopoiesis through control of crosstalk between integrin- and TPO-mediated pathways 
implicated in the megakaryocyte maturation and platelet release process (Takizawa et al., 
2008). Furthermore, Lnk plays an important role in stabilizing thrombus formation through 
positive regulation of integrin signalling pathways. In this way, it contributes to platelet 
cytoskeleton rearrangement and spreading (Takizawa et al., 2010). 
 
Fig. 3. Lnk family signalling pathways in haematopoietic cells  
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Studies on Lnk-/- and APS-/- mast cells demonstrated their physiological implication in mast-
cell functions. Lnk regulates SCF-mediated signalling pathways controlling proliferation 
(MAPK and JNK) and migration (Rac and p38MAPK) in these cells (Takizawa et al., 2006; 
Simon et al., 2008). These functions are mainly mediated by binding of its SH2 domain to 
specific effectors involved in actin rearrangement. On the other hand, APS controls actin 
cytoskeleton and magnitude of degranulation induced by FcRI receptor cross-linking 
(Kubo-Akashi et al., 2004). Besides its specific expression in the haematopoietic system, Lnk 
is also highly expressed in endothelial-like cells in the aorta-gonad-mesonephros (AGM) 
region and in endothelial progenitor (EPC) and mature cells [EC](Nobuhisa et al., 2003; 
Fitau et al., 2006; Kwon et al., 2009). Fitau et al. have shown that the pro-inflammatory 
cytokine TNF- rapidly evokes Lnk phosphorylation together with down-regulation of 
vascular cell adhesion molecule 1 (VCAM-1) expression in activated vascular ECs. These 
results implicate Lnk as an important negative regulator of TNF-α signalling pathway (Fitau 
et al., 2006). 
3.3 The Cbl family 
3.3.1 Origin, cell expression and structure  
The Cbl (for Casitas B-lineage Lymphoma) family comprises multidomain regulators with 
dual function, as E3 ubiquitin ligases and adaptor proteins. It consists of three mammalian 
homologues, c-Cbl, Cbl-b and Cbl-c/Cbl-3 (Blake et al., 1991; Keane et al., 1995, 1999), as 
well as invertebrate orthologues (Thien & Langdon, 2001). The first isoform of this family 
identified was the oncogenic protein v-Cbl, a Gag-fusion transforming protein of Cas NS-1 
retrovirus, which induces pre- and pro-B lymphomas and the transformation of rodent 
fibroblasts (Langdon et al., 1989). The cellular form, c-Cbl was subsequently cloned and 
revealed that v-Cbl was a result of a large truncation of its C-terminal portion and that 
overexpression of c-Cbl did not promote tumorigenesis. The 120 kDa c-Cbl protein is 
ubiquitously expressed, primarily cytoplasmic, with highest expression levels in 
haematopoietic organs (thymus) and testis. In contrast, Cbl-3 is expressed mainly in 
epithelial cells of the gastrointestinal system. 
All Cbl proteins share highly conserved N-terminal regions, but their C-terminal sequence 
differs and is less well-conserved (Figure 1).  The N-terminal half encompasses two 
important domains: a tyrosine kinase-binding (TKB) and a C3HC4 zinc-binding RING finger 
domains, both separated by a small linker sequence. The TKB domain contains three distinct 
subdomains comprising a four-helix bundle (4H), a calcium-binding EF hand and a 
modified SH2 domain, all necessary for its function as phosphotyrosine-binding (PTB) 
module. The second conserved domain in the N-terminal region is a zinc-binding RING 
finger domain responsible for the E3 ubiquitin ligase activity of c-Cbl (Joazeiro et al., 1999). 
The C-terminal sequences are less homologous among Cbl proteins; however, they all have 
proline-rich regions that are involved in numerous SH3-domain interactions (Keane et al., 
1995) and the major sites of tyrosine phosphorylation, which enable interactions of Cbl with 
SH2 domain containing proteins. The C-terminus of c-Cbl, Cbl-b contains a sequence 
homologous to both the leucine zipper (LZ) and the ubiquitin associated (UBA) domain. The 
LZ domain has been shown to mediate Cbl dimerization (Bartkiewicz et al., 1999; Liu et al., 
2003), while only Cbl-b and not c-Cbl can bind to ubiquitin through its UBA domain (Davies 
et al., 2004). 
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3.3.2 Signalling binding partners 
The TKB domain is unique to Cbl proteins and its feature role is to determine Cbl substrate 
specificity by engaging specific phosphorylated tyrosine residues on proteins that are to be 
ubiquitylated by Cbl. Some of Cbl TKB domain targets include: receptor tyrosine kinases 
(RTKs), non-receptor protein tyrosine kinases (PTKs) of the Syk family, several adaptors and 
regulatory proteins (Table 3). In contrast to SH2 binding motif, the TKB phosphotyrosine 
recognition consensus sequence displays an specificity conferred by amino acid residues C-
terminal to the tyrosine (Lupher et al., 1997). These findings argue that interaction of the 
TKB domain with RTKs may then primarily be to ensure the appropriate orientation of the 
receptor such that Cbl’s E3 ligase activity can promote the transfer of ubiquitin. TKB domain 
interactions may therefore determine the number of ubiquitin molecules transferred to the 
substrate and thus regulate the extent to which activated RTKs are ubiquitylated. Thus the 
TKB domain appears to have at least two important roles in regulating E3 ligase activity, 
and, as such, it is functionally more complex than classical SH2 or PTB domains. 
 
Binding domain Binding partner  Signalling receptor 
TKB Syk, Zap-70 AgR 
 c-Src AgR, GFR, CyR 
 APS HR 
 EGFR, PDGFR GFR 
RING E2s(Ub-conjugated enzyme) GFR, AgR, CyR 
Pro-rich Grb2 GFR 
 Nck GFR, AgR 
 Src kinases GFR, AgR, CyR 
pY Vav, CrkL, Src kinases AgR 
 p85 (only with c-Cbl) AgR, GFR 
UBA Ub (only with Cbl-b) GFR 
LZ c-Cbl, Cbl-b GFR, HR 
AgR, antigen receptor; GFR, growth factor receptor; CyR, cytokine receptor; HR, hormone receptor. 
Table 3. Signalling proteins bound to the different domains and motifs of c-Cbl/Cbl-b 
proteins. 
Separating the TKB and the RING domains, a short linker sequence extends which has been 
shown crucial for Cbl ubiquitin ligase activity (Thien et al., 2001). The TKB domain makes 
intramolecular contacts with the linker α-helix and these contacts are centred on conserved 
residues Y368 and Y371 in human c-Cbl (Zheng et al., 2000). Interestingly, deletion of these 
tyrosines causes c-Cbl to become oncogenic (Thien et al., 2001). Molecular modelling data 
predicted that this structural alteration, in addition to loss of E3 activity, is required to 
activate fully the oncogenic potential of Cbl proteins. The second highly conserved domain 
among all Cbl proteins is the RING finger. In vitro ubiquitylation assays proved that the 
highly conserved Cbl RING finger has intrinsic E3 ligase activity and can independently 
recruit E2s or ubiquitin-conjugating (Ubc) enzymes for the transfer of ubiquitin to substrates 
(Joazeiro et al., 1999). The structural integrity of the RING finger domain is an absolute 
requirement for Cbl proteins to function as E3 ligases. Moreover, the RING finger domain 
acts in concert with the TKB domain to facilitate ubiquitylation and degradation of activated 
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PTKs, with the TKB domain conferring substrate specificity and the RING finger bringing in 
an E2 ubiquitin-conjugating enzyme. The carboxy-terminal half of c-Cbl is rich in proline 
residues, which contributes at least 15 and 17 potential SH3-domain-binding sites in c-Cbl 
and Cbl-b respectively, while Cbl-3 encodes five potential SH3-binding sites. Moreover, the 
proline-rich region in c-Cbl is also required for the ubiquitylation and proteasomal 
degradation of activated forms of Src (Yokouchi et al., 2001). In this case, the Cbl substrate is 
targeted by proline sequence interactions, rather than the TKB domain. 
c-Cbl and Cbl-b are prominent substrates of RTKs and PTKs following stimulation of 
diverse cell surface receptors, as they possess major sites of tyrosine phosphorylation at 
their C-terminal part that enable them to interact with different SH2 domain containing 
proteins. Indeed, several studies have demonstrated the important role of tyrosine 
phosphorylation of Cbl proteins for their adaptor function, as well as for their E3 activity. 
The best-characterized phosphorylation sites are Y700, Y731 and Y774 in human c-Cbl and 
Y709 and Y665 in Cbl-b (Tsygankov et al., 1996; Keane et al., 1995). These residues are 
efficiently phosphorylated by Syk and the Src-family kinases Fyn, Yes and Lyn, but not by 
Lck or ZAP-70. An important difference between c-Cbl and Cbl-b is the unique presence of 
Y731 in c-Cbl which binds the SH2 domain of the p85 regulatory subunit of PI3K. 
Surprisingly, this association enables c-Cbl to function as a positive regulator by recruiting 
PI3K to the cell membrane (Hunter et al., 1999). 
3.3.3 E3 ligase activity and adaptor function 
The multi-domain nature of Cbl allows it to interact, directly or indirectly, with a wide 
range of signalling molecules. In this way, activated Cbl proteins act essentially as 
attenuators of cellular signals by exerting their function as E3 ubiquitin ligases or as 
adaptors/inhibitors proteins towards PTK pathways.    
Cbl E3 ligase activity. Extensive biochemical studies have demonstrated Cbl-mediated 
ubiquitylation of its substrates (Figure 4). It is clear that ubiquitylation of a targeted receptor 
occurs in parallel to the onset of receptor internalization and continues to occur throughout 
the endosomal pathway. One of the best-studied examples of how Cbl-mediated 
ubiquitylation affects receptor trafficking, and helps terminate the signal from the activated 
receptor complex, is the EGF receptor (EGFR). This multistep process was initially described 
in C. elegans, where SLI-1 (the Cbl orthologue) was shown to negatively regulate signalling 
downstream of the LET-23 receptor [the EGFR orthologue] (reviewed in Thien and 
Langdon, 2001). This mechanism has become a model for the regulation of other RTKs by 
Cbl. 
Cbl as an adaptor/inhibitor protein. An alternative way for Cbl to ubiquitylate EGFR is 
indirect and utilises its adaptor/inhibitor function by binding to the adaptor protein growth 
factor- receptor bound-2 (Grb2). One of the first proteins to be recruited into the complex is 
Grb2, which can recruit Cbl proteins from the cytoplasm to the plasma membrane through 
interactions between the proline-rich region of Cbl proteins and the N-terminal SH3 domain 
of Grb2. In this way, Cbl competes with the guanine-nucleotide-exchange factor son-of-
sevenless (SOS) to bind Grb2, thereby blocking signalling through the Ras–mitogen-
activated protein kinase (MAPK) pathway and inhibiting proliferation. 
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3.3.4 Signalling pathways in the haematopoietic and immune systems 
Cbl gene deletions primarily affected the haematopoietic, immune and metabolic systems. A 
recent study on c-Cbl-/- HSC showed that the number and ability to reconstitute the 
haematopoietic system was increased in these cells compared to wild-type HSC. These 
results suggested that Cbl ubiquitin-mediated protein degradation is important for HSC 
homeostasis (Rathinam et al., 2008). Furthermore, it was shown that c-Cbl is capable of 
controlling HSC development and function through negative regulation of TPO-dependent 
STAT5 activation, an important pathway for HSC maintenance. Indeed, c-Cbl-deficient HSC 
displayed TPO hypersensibility, as well as increased levels of STAT5 and its activated form, 
phospho-STAT5. Thus, these findings underline the role of c-Cbl as important modulator of 
the TPO/Mpl/JAK/STAT5 signalling pathway in HSCs. 
The importance of c-Cbl and Cbl-b in immunity and immune receptor signalling pathways has 
been demonstrated clearly by the phenotypes of their respective gene knockout mice. Both c-
Cbl−/− and Cbl-b−/− mice display hyperactive signalling downstream of the TCR. Loss of either 
Cbl protein results in lower activation threshold for signalling through the TCR, 
hypersensitivity to low affinity/avidity engagement of the receptor, and activation of 
downstream signalling pathways without the normal requirement for co-receptor stimulation 
(Figure 4) (Murphy et al., 1998; Naramura et al., 1998; Bachmaier et al., 2000; Chiang et al., 
2007). Interestingly, these c-Cbl and Cbl-b phenotypes are restricted to thymocytes and T-cells, 
respectively, reflecting a difference in tissue distribution with c-Cbl more prominent in the 
thymus and Cbl-b highly expressed in peripheral T-cells. Loss of Cbl-b dramatically increases 
T-cell activation threshold and uncouples T-cell activation from the requirement for CD28 co-
stimulation, thus leading to spontaneous autoimmunity (Gronski et al., 2004). 
Cbl proteins have been also shown to differentially modulate BCR-dependent signalling. 
Loss of c-Cbl in primary B cells showed a significant inhibition of BCR-mediated signalling 
mainly caused, not by down-regulation of Syk, but instead by up-regulation of Lyn kinase 
(Shao et al., 2004). In contrast, Cbl-b negatively regulates BCR-mediated signalling, this 
time, by down-regulating Syk in primary B cells (Sohn et al., 2003). Furthermore, the activity 
of Cbl proteins as adaptors was also implicated in the effect of Cbl proteins on B-cell 
activation. In this case, it has been shown that c-Cbl negatively regulates the phospholipase 
C-2 (PLC-2) pathway in B cells, while Cbl-b was shown to positively regulate this same 
pathway (Yasuda et al., 2002). 
Studies carried out with cell lines have demonstrated that both c-Cbl and Cbl-b negatively 
regulated FcRI-mediated mast cell activation (Figure 4). However, experiments on primary 
mast cells derived from c-Cbl and Cbl-b-deficient mice revealed a more profound effect with the 
lack of Cbl-b than of c-Cbl (Zhang et al., 2004). Cbl-dependent FcRI down-regulation occurs 
mainly via Cbl E3 ubiquitin ligase activity that promotes receptor  and  multiubiquitination, 
providing signals for receptor internalization and sorting into lysosomal compartments for 
degradation. Interestingly, Syk activity is required for c-Cbl-dependent ubiquitylation of FcRI 
receptor (Paolini et al., 2002). On the other hand, Cbl proteins can also down-modulate engaged 
FcRI through its adaptor function by interacting with molecules involved in clathrin-mediated 
endocytosis (Molfetta et al., 2005). Remarkably, Cbl proteins also negatively regulate mast cell 
activation by selectively ubiquitinating and degrading the activated kinase form of Lyn and Syk 
proteins (Paolini et al., 2002; Kyo et al., 2003; Qu et al., 2004).   
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Fig. 4. A) Model of Cbl ligase activity. B) Schematic model of Cbl signalling pathways in T 
and mast cells 
c-Cbl also participates in the modulation of monocyte/macrophage signalling mediated by 
Fcand Colony Stimulating Factor (CSF)-1 receptors through its adaptor functions. c-Cbl is 
capable of attenuating CSF-1-mediated signalling by binding to a phosphotyrosine residue 
of this receptor and then ubiquitylating and targeting it for degradation. Lastly, c-Cbl also 
appears to play a negative regulatory role in platelets as well. This is not so surprising 
considering that Syk kinase has a biological function in these cells, a known substrate of c-
Cbl. The contribution of c-Cbl-dependent ubiquitylation of Syk to the negative effect of c-
Cbl on platelet functions is not yet understood, however, it is possible that the biological 
role of c-Cbl in platelets consists in preventing unwanted platelet activation in vivo by 
increasing the threshold of platelet activation.  
3.3.5 Regulation of Cbl function 
Cbl proteins are potent regulators of cell function and development through their adaptor 
function and ligase activity. It is therefore necessary that the Cbl proteins are at their turn, 
subject to complex and sophisticated regulatory mechanisms that fine-tune the effects that 
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these proteins have on signalling (Ryan et al., 2006). These include: cis-acting structural 
elements that prevent inappropriate E3 activity until the Cbl proteins interact with their 
substrate, degradation of the Cbl proteins, inhibition of Cbl protein function mediated by 
protein interactions, deubiquitination of the Cbl substrates, and negative regulation of 
trafficking of the ubiquitinated Cbl substrates. Therefore, abnormal Cbl regulation can lead 
to pathological conditions such as immunological and malignant diseases, thus 
underscoring the essential role of Cbl in normal homeostasis. 
3.4 The SOCS family 
3.4.1 Origin, structure and cellular expression 
The SOCS (for Suppressors Of Cytokine Signalling) proteins are a family of intracellular 
molecules that negatively regulate the strength and duration of cytokine receptor signalling 
cascades, notably the JAK/STAT pathway. This family consists of eight members, CIS and 
SOCS1-7 that share structural and functional homology. The first family member identified 
was CIS (for Cytokine-Inducible SH2-containing protein) cloned as an early gene 
differentially induced following IL-3 and EPO exposure (Yoshimura et al., 1995). The second 
member identified, SOCS1 (also known as JAB for JAK-Binding protein or SSI for STAT-
induced STAT Inhibitor) was identified simultaneously by three separate groups (Starr et 
al., 1997; Endo et al., 1997; Naka et al., 1997). SOCS-2 and SOCS-3 were cloned using 
distantly related expressed sequence tags [ESTs] and the rest of the members (SOCS4-7) 
were identified on the basis of a conserved C-terminal amino acid sequence using various 
DNA databases (Starr et al. 1997; Minamoto et al., 1997; Hilton et al., 1998). All members of 
the SOCS family have a similar tripartite domain organization composed of a variable N-
terminal region, followed by a central SH2 domain and a conserved C-terminal SOCS box 
domain (Fig. 1).  SOCS1 and SOCS3 differ from other family members in that they possess 
an extended SH2 domain at the N-terminus (for SOCS1 and SOCS3) or the C-terminus (for 
SOCS3) of this domain. Additionally, they also present at their N-terminal region and 
adjacent to their SH2 domain, a Kinase-Inhibitory Region (KIR) required for inhibition of 
JAK kinase activity (Yasukawa et al., 1999; Sasaki et al., 1999). Another exception is SOCS7 
which is unique in its possession of a proline-rich N-terminus and a nuclear localisation 
signal. 
SOCS molecules expression is controlled at the transcriptional, translational and post-
translational levels. Many SOCS genes contain STAT-binding sequences in their promoter 
region and their STAT-dependent transcription can be differentially regulated in a factor- 
and tissue specific manner. SOCS proteins are often low or undetectable at the basal level in 
unstimulated cells and their expression is rapidly induced to a variable extent in different 
cell types and tissues by immunoregulatory cytokines, colony stimulating factors, growth 
factors and hormones that signal via JAK-STAT pathway or via RTK [Table 4] (Starr et al., 
1997). Certain cytokines that do not signal via JAK kinases or RTKs, and a number of non-
cytokine ligands can also induce SOCS gene expression, such as TNF signalling and 
bacterial products such as LPS and CpG DNA which signal via Toll-like receptors (TLR). 
Because SOCS genes are induced by cytokines and the corresponding proteins inhibit 
further cytokine-induced signalling, SOCS proteins are believed to form part of a classical 
negative feedback loop mechanism. Northern blot analysis of murine tissues has shown that 
CIS and SOCS2 mRNA was ubiquitously expressed, with expression being particularly 
www.intechopen.com
 
Hematology – Science and Practice 
 
64
strong (CIS) or weak (SOCS2) in kidney, lung, liver, heart, testis and male spleen 
(Yoshimura et al., 1995; Starr et al., 1997). SOCS1 and SOCS3 mRNA was detected at 
different levels in adult haematopoietic organs such as the thymus and spleen and to some 
extent in other organs like lung, spleen and testis (Starr et al., 1997). However, SOCS3 show 
high expression in fetal liver (Marine et al., 1999). Although some of the SOCS members 
appear to be co-expressed in only a few organs, the in vivo expression of SOCS genes may be 
more pronounced than is detectable by Northern hybridisation, since most cell types seem 
to depend on cytokine stimuli for SOCS induction. 
3.4.2 Signalling targets 
The different domains in the SOCS proteins allow them to bind to the cytokine receptors, 
associated JAKs or other signalling molecules and to attenuate signal transduction directly 
or indirectly by targeting the receptor complex for ubiquitin-mediated degradation in 
proteosomes. The N-terminal region of the SOCS proteins is variable in length and 
sequence. In SOCS1 and SOCS3, there is a 12 amino acid sequence adjacent to the SH2 
domain that is essential for the inhibition of JAK2 kinase called KIR. This sequence is 
supposed to function via a conserved tyrosine residue as a pseudo-substrate, lodging in the 
catalytic cleft to block further JAK kinase activity. Removal of this tyrosine does not affect 
binding of the SOCS proteins to the kinase, but does abrogate its inhibition (Sasaki et al., 
1999).  Inded, a SOCS1-KIR mimetic peptide is sufficient to inhibit IFN-mediated JAK2 
activity in primary cells (Waiboci et al., 2007). The role of the remaining N-terminal region 
among the SOCS family members has yet to be elucidated. 
The central SH2 domain determines the target protein for degradation of each SOCS protein. 
It binds to distinct phosphorylated tyrosine motifs on SOCS target proteins (Table 4). Once 
the SH2 domain binds to its specific target, it brings other domains in proximity to the target 
protein, directing degradation of the appropriate protein. Mutagenesis studies allowed the 
identification of small regions at the N-termini of SOCS1 and SOCS3, and at the C-terminus 
of SOCS3 SH2 domains, critical for phosphotyrosine binding. These regions have been 
defined as an N- and C-extended SH2 domain (N-ESS and C-ESS, respectively). The solved 
structure of SOCS3 SH2 domain had shown that the N-ESS sequence directly contacts the 
phosphotyrosine-binding loop of the kinase and determines its orientation (Babon et al., 
2006). The C-ESS of SOCS3 forms part of the SH2 domain that is spatially displaced by a 35 
amino acid PEST [for Proline, Glutamic acid (E), Serine and Threonine rich sequence] 
insertion. This sequence is thought to signal for rapid proteolytic degradation. It is therefore 
not surprising that removal of this sequence lowers SOCS3 turnover without affecting the 
SH2 domain folding and function (Babon et al., 2006). Since other SOCS members contain 
putative PEST sequences, this may prove to be a common mechanism for regulation of 
SOCS protein levels. 
The SOCS proteins are substrate recognition factors for an E3 ligase that targets their specific 
cargo for ubiquitin-mediated degradation. They serve this function by binding to the E3 
complex via the highly conserved SOCS box domain at their C-terminus. The SOCS box is a 
40 amino acid motif found not only in the SOCS family members, but also in a vast number 
of proteins. The SOCS box consists of a three--helical structure bound to an E3 ubiquitin 
ligase complex that in turn covalently binds ubiqutin to lysines in the target protein. The N-
terminus of the SOCS box mediates interaction with Elongin C/B, while the C-terminus of  
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SH2 partner Inducer system Signalling system 
inhibited 
CIS EPOR, PRLR, 
Leptin R 
EPO, IL-2/3/6, IFN, PRL, 
GH, Leptin 
EPO, PRL, IL-2/3, GH 
SOCS1 JAK2, IFNGRI EPO, TPO, GM-CSF, G-
CSF,M-CSF,IL-
2/4/6/7/9/10/13/15, 
PRL, LPS, TNF, GH, In, 
CpG DNA  
IL-2/4/6/7/12/15, 
IFN//, LIF, TNF, 
EPO, TPO, GH, PRL, In, 
Leptin 
SOCS2 GHR, Leptin R GH, IL-6, IFN/, LIF IL-6, GH, IGF-1 





2/6/9/10/13, GH, LPS, 
EGF, IFN/, LIF, EPO, 
GM-CSF, PRL, In, Leptin 
IL-2/4/6/9/11, 
IFN//, LIF, EPO, 
GH, PRL, In, Leptin 
SOCS4, 
SOCS5 
EGFR EGF, IL-6 EGF, IL-4/6 
SOCS6, 
SOCS7 
IRS2/4, IR In, IGF In, IGF 
In, insulin; PRL, prolacftin. 
Table 4. Signalling partners, transduction pathways and factors regulating SOCS protein 
expression and function. 
the SOCS box directs the SOCS/Elongin C/B association with Cullin 5 (Cul5) scaffold 
protein (Zhang et al., 1999). The latter one recruits the stabilizing RING finger protein Rbx 
and allows Cul5 to bind to an E2 ubiquitin-conjugating enzyme. The resulting complex 
SOCS/Elongin B/C/Cul5/Rbx/E2 forms a functional E3 ubiquitin ligase (Figure 5a). The 
SOCS1-SOCS box has been shown to be capable of driving the ubiquitination of specific 
proteins such as TEL-JAK2 fusion and Vav1, and only in very few cases the receptor 
complex for subsequent degradation through the proteosome (Frantsve et al., 2001; De 
Sepulveda et al., 2000; Irandoust et al., 2007; Verdier et al., 1998). The importance of the 
SOCS box has been further shown by in vivo targeted deletion of SOCS1 and SOCS3 in mice 
that resulted in partial loss of SOCS function with enhanced IFN and G-CSF signalling, 
respectively (Zhang et al., 2001).  
3.4.3 Regulation of cytokine receptor signalling pathways 
The structural analysis of the SOCS molecules revealed they can control cytokine receptor 
signalling by several mechanisms (Figure 5): 
(1) Direct inhibition of intrinsic kinase activity by binding to JAKs.  Immunoprecipitation 
assays revealed that both SOCS1 and SOCS3 were able to co-precipitate with JAK kinases 
upon cytokine stimulation, and that this association blocked JAK kinase activity, although 
with a different affinity and kinetics (Endo et al., 1997; Sasaki et al., 1999). Structure-function 
studies using truncated versions of SOCS1 identified the regions essential for SOCS-JAK 
association and for inhibition of JAK activity. SOCS1 inhibits tyrosine kinase activity upon 
interaction with phosphorylated tyrosine Y1007 located in the activation loop of JAK.  
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Fig. 5. A) Schematic representation of the SOCS box function, B) Mechanisms of suppression 
by the SOCS proteins. 
However, complete inhibition of the kinase activity requires not only the SH2 domain but 
also the KIR region (Narazaki et al., 1998; Nicholson et al., 1999). The critical amino acids for 
the KIR region’s function are conserved between SOCS1 and SOCS3, suggesting a common 
inhibitory mechanism for these two family members. 
(2) Indirect inhibition of JAKs by binding to the receptor. As with SOCS1, the SOCS3 SH2 
domain was initially shown to interact with Y1007 in JAK2, albeit with lower affinity than 
SOCS1. However, subsequent studies demonstrated that SOCS3 SH2 domain exhibited a 
higher affinity for phosphotyrosine residues located within the receptor subunits than for 
JAK2 (Sasaki et al., 1999). Accordingly, it was found that SOCS3 associated with higher 
affinity with phosphorylated residues in the IL-6 receptor subunit, gp130, notably Y759, 
than with the activation loop of JAKs (Nicholson et al., 2000). SOCS3, therefore, in contrast 
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to SOCS1, has to be recruited to the receptor complex in order to inhibit IL-6 signal 
transduction (Schmitz et al., 2000). Subsequently, SOCS3 might inhibit the kinase activity of 
JAKs through the pseudo-substrate, KIR, in the same way as SOCS1, but only after 
recruitment and binding to critical phosphotyrosine residues in the cytokine receptor. Given 
that SOCS1 and SOCS3 can interact with both receptor and JAK, a two-step interaction 
model has been proposed, whereby the SOCS1/3 SH2 domains are first recruited to the 
receptor and subsequent bi-modal binding to nearby JAK through the SH2 domain and KIR 
region results in a high affinity interaction, inhibition of JAK kinase activity and potential 
proteosomal degradation. 
(3) Blocking binding of downstream signalling molecules to the receptor. This mechanism 
has been shown for CIS and SOCS2 for EPO and GH signalling inhibition, respectively. 
Upon stimulation of the receptors, the SOCS proteins bind to tyrosine residues at the 
membrane distal region of receptor chains that are docking sites for downstream signalling 
molecules, such as STAT5 or SHP-2. By masking these phosphorylated residues, CIS/SOCS2 
competes with STAT thereby down-modulating the signalling (Yoshimura et al., 1995; Ram 
& Waxman, 1999). On the other hand, SOCS3-mediated inhibition of signalling via EpoR, 
gp130 and LeptinR could partially result from competitive inhibition of SHP-2 binding to 
gp130, LeptinR, and EpoR, resulting in the blockade of SHP-2-mediated ERK activation 
(Schmitz et al., 2000; Bjorbaek  et al., 2001; Sasaki et al., 2000). 
(4) Ubiquitination and subsequent proteasomal degradation of JAKs and receptor. Studies 
on EPO receptor using proteasome inhibitors showed that these compounds protected the 
EpoR and STAT5 from the normal reduction in phosphorylation upon CIS expression, 
indicating proteasome involvement of both EPO-receptor and STAT5 inactivation (Verdier 
et al., 1998). These results allow proposing a model where the phosphorylated target 
molecules may become a substrate of the proteolytic machinery by binding to SOCS. In this 
situation, the SOCS box acts as an adaptor molecule, bringing into this complex the Elongin 
B/C/E3 ligase for ubiquitination of the target protein. Subsequently, the substrate and the 
associated SOCS proteins may be destroyed, and the cell is ready to respond again to 
stimulation. Therefore, targeting the signalling proteins for degradation by the SOCS box 
seems to be another mechanism by which cytokine signalling might be inhibited under 
physiological levels of SOCS proteins. 
3.4.4 Regulation of SOCS proteins 
Besides elaborate transcriptional regulation, another control point of the expression of SOCS 
molecules is their protein stability. SOCS proteins exhibit a rapid turnover rate, and the half 
lives of SOCS1, SOCS2 and SOCS3 have been estimated to be less than 2 h (Siewert et al., 
1999). Several mechanisms have been proposed to regulate SOCS expression. The presence 
of a PEST sequence in SOCS3 appears to mediate non-proteosomal degradation, while SOCS 
box-dependent ubiquitination of SOCS3 on lysine 6, at least in vitro, contributes to 
proteosomal degradation of the SOCS3 protein (Sasaki et al., 2003). Furthermore, SOCS3 is 
uniquely phosphorylated within the SOCS box on Y204 and Y221 and this appears to have 
two consequences, interaction with the Elongin B/C complex is lost, destabilizing the 
SOCS3 protein, and signalling through the Ras/MAPK pathway can be potentiated (Haan et 
al., 2003; Cacalano et al., 2001). Nevertheless, the full implication of SOCS3 phosphorylation 
on its regulation remains to be explored. 
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4. Animal models of inhibitory adaptors: Definition of their physiological 
significance 
Central to understanding the physiological role of families of inhibitory adaptors in the 
haematopoietic and immune systems, has been the generation of mice deficient for these 
proteins when possible. This has also helped dissect regulatory and/or compensatory 
mechanisms through the functional, complete or partial, reconstitution in these mice, in 
particular for members of multi-gene families. These approaches have allowed 1) analyse 
changes in the expression level of the adaptor that can also affect its signalling pathway; 2) 
establish how deficiency of an adaptor can have dramatically different effects in different 
cell lineages; 3) understand the functional synergy between members of the same family of 
adaptors; 4) identify null mutations leading to the complete absence of some cell types, 
while leaving others with no discernable defect and 5) define how some deficiencies are 
selective within a cell type, disrupting only particular pathways while leaving others intact. 
Mice deficient for the different families of inhibitory adaptors discussed in this chapter have 
certainly provided important new insights into the biology and function of these adaptors. 
However, in some cases, these animal models have also raised important questions 
regarding the mechanisms of action of these regulators and their potential therapeutic 
application. 
4.1 Dok deficient mice 
Although Dok-1, Dok-2, and Dok-3 have been shown to act as negative regulators 
downstream of a wide range of immunoreceptors, cytokine, and LPS receptors mediated 
signalling, insights into their physiological importance in immune cells have and will 
continue to come from studies with mice or cells lacking individually or in combination 
Dok-1, Dok-2, and Dok-3. Dok-1 or Dok-2-deficient mice displayed normal steady-state 
haematopoiesis. By contrast, mice lacking both Dok-1 and Dok-2 succumbed to a 
myeloproliferative disease resembling human chronic myelogenous leukaemia (CML) and 
chronic myelomonocytic leukaemia (CMMoL) at around one year of age (Yasuda et al., 2004; 
Niki et al., 2004) [Table 5]. These animals displayed medullary and extramedullary 
hyperplasia of granulocyte/macrophage progenitors with leukemic potential, and their 
myeloid cells showed hyperproliferation and hypo-apoptosis upon treatment and 
deprivation of cytokines, respectively. Consistently, the mutant myeloid cells showed 
aberrant Ras/MAP kinase and Akt activation upon cytokine stimulation. Strikingly, ablation 
of Dok-1 and Dok-2 markedly accelerated leukaemia and blastic crisis onset in bcr-abl 
transgenic mice known to develop a CML-like disease. These results demonstrate the critical 
role of Dok-1 and Dok-2 in myeloid homeostasis and suppression of leukaemia. 
Interestingly, half of the double-deficient mice also developed histiocytic sarcoma (HS) of 
macrophage origin. These results suggest an involvement of additional genetic changes. 
Similar to Dok-1 and Dok-2 deficiency, Dok-3 inactivation did not result in development of 
aggressive tumors in haematopoietic cells (Ng et al., 2007). However, ablation of all three 
Dok proteins (Dok-1/2/3) in mice has recently shown drastic phenotypic consequences. 
These mice showed earlier mortality due to development of aggressive HS with multiple 
organ invasions, but no incidence of other types of tumors (Mashima et al., 2010). This 
disease is a haematological malignancy characterized by cells displaying a tissue 
macrophage-like (histiocytic) morphology (Grogan et al., 2008).  Indeed, loss of Dok-1/2/3 
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causes aberrant proliferation of macrophages in the lung, already detectable before the onset 
of morphologically recognizable HS. These cells displayed an exaggerated proliferative 
response to M-CSF or GM-CSF compared to wild type littermates. These results suggest that 
Dok proteins can mutually compensate and inhibit macrophage proliferation and therefore 
suppress the aggressive transformation of HS. 
4.2 Lnk/APS/SH2-B deficient mice 
Mice deficient for members of this family have demonstrated the positive (SH2-B) and 
negative (Lnk and APS) physiological role of these adaptors in growth factor, cytokine, and 
immune receptors signalling (Table 5). Deletion of the SH2B1 gene resulted in severe 
obesity, hyperphagia and both leptin and insulin resistance as well as infertility, which 
might be a consequence of resistance to IGF-1 (Ohtsuka et al., 2002; Ren et al., 2005). Thus, 
SH2-B-deficient mice support a role for this adaptor as a positive regulator of JAK2 
signalling pathways initiated by leptin, insulin and potentially, by IGF-1. 
Interestingly, APS-deficient mice also displayed an insulin-related phenotype. They showed 
a hypersensibility to insulin and enhanced glucose tolerance, a finding that is consistent 
with APS playing a negative role in insulin signalling (Minami et al., 2003). Moreover, these 
mice present also a haematopoietic phenotype with defects in degranulation of mast cells 
and cytoskeleton rearrangement in both mast and B-1 cells (Kubo-Akashi et al, 2004; Iseki et  
 
Gene Approach System Mouse phenotype/Human disease 
Dok-1 
Dok-2 
KO mu Impaired immunoreceptor signaling in lymphocytes, 
allergic responses in mast cells, enhanced ERK 
signaling, hyperresponsiveness to LPS 
Dok-1/2 KO mu MPN, Lupus Renal disease/CML, CMMoL 
Dok-
1/2/3 
KO mu HS 
    
Lnk KO mu MPN-like (ET/PMF), CML (aged mice) 
 Tg mu Impaired lymphopoiesis 
 Mu (SNP) hu MPN, autoimmune, cardiovascular and 
inflammatory diseases 
APS KO mu Insulin hypersensitivity, enhanced glucose tolerance, 
enhanced B1 cells proliferation 
 Tg mu Reduced B1 and B2 cell number, impaired B-cell 
development and BCR-dependent proliferation, 
reduced mast cell degranulation and actin assembly 
SH2B KO mu Severe obesity, hyperphagia, increased leptin and  
insulin resistance, infertility 
    
c-Cbl KO mu Enlarged thymus, splenomegaly, extramedullar 
haematopoiesis, enhanced thymocyte function/ 
myeloid malignancies 
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Gene Approach System Mouse phenotype/Human disease 
c-Cbl Mu hu AML, MPD/MPN, aCML, JMML 
Cbl-b KO mu Impaired immunological tolerance, autoimmune 
diseases with inflammatory organ and tissue 
damage, enhanced peripheral T-cell function, 
rejection of certain tumours 
c-Cbl/ 
Cbl-b 
KO mu Embryonic lethal 
 T-cell KO mu Autoimmune-like vasculitis, SLE-like autoimmune 
disease 
    
CIS KO mu No specific phenotype 
 Tg mu Fewer T-cells, NK, and NK-T cells, lactation 
deficiency, similar phenotype to STAT5 KO 
SOCS1 KO mu perinatal lethality, enhanced IFN production and 
responsiveness, lymphopenia and inflammation 
with multi-organ infiltration 
 Tg(Tcell) mu Inhibited T-cell response to IFN, IL-6 and IL-7, 
increased CD4+T-cells, reduced peripheral T-cell 
activation  
  hu Increased expression in Th-driven inflammatory 
diseases (RA, UC, Crohn, dermatitis), decreased 
expression and/or hyper-methylation in certain 
cancers 
SOCS2 KO mu Gigantism, deregulated GH signalling 
 Tg mu Gigantism 
SOCS3 KO mu Embryonic lethality due to placental deficiency, 
erythrocytosis, deregulated LIF response 
 Tg mu Embryonic lethality due to anemia 
 Tg(Tcell) mu High TGF1 and IL-10 production 
 Mu (SNP) hu Allergic diseases  
  hu Increased expression in Th2-driven asthma patients 
and inflammatory diseases, hyper-phosphorylation 
in MPN 
SOCS5 KO mu No specific phenotype 
 Tg mu Reduced IL-4-mediated STAT6 activation, reduced 
Th2 development and cytokine production 
SOCS6 KO mu Mild growth retardation 
SOCS7 KO mu Growth retardation (strain-dependent), 
hypoglucemia, hydrocephalus, altered glucose 
homeostasis, enlarged pancreatic islets 
KO, knock out; Tg, transgenic; Mu, mutations; hu, human; mu, murine, RA, theumatoid arthritis; UC, 
ulcer colitis. 
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al., 2004). These results suggest a negative role for APS in controlling actin dynamics in 
these cells. Furthermore, APS-deficient mice display an increase in B-1 cells in the peritoneal 
cavity and humoral responses to type-2 antigen, indicating a negative regulatory role for 
APS in BCR-mediated cell proliferation and cytoskeletal regulation. 
By contrast, mice deficient for Lnk display a profound perturbation in haematopoiesis that 
confirmed its role as a key negative regulator of cytokine signalling in the haematopoietic 
system. Indeed, these mice exhibit splenomegaly together with fibrosis, expansion of HSC, B 
lymphoid and myeloid progenitors that confer an enhanced repopulating ability. Lnk-deficient 
mice have also revealed an important role for Lnk in B-cell lymphopoiesis, megakaryopoiesis 
and erythropoiesis, as a result of the absence of negative regulation of SCF, TPO and EPO 
signalling pathways. One important feature of the Lnk-/- mice phenotype is its resemblance to 
human myeloproliferative neoplasms (MPN): hypersensitivity to cytokines, increased number 
of haematopoietic progenitors, high platelet counts, splenomegaly together with fibrosis and 
extramedullary hematopoiesis (Velazquez et al., 2002; Campbell & Green, 2008). This has 
suggested an important role for Lnk in the development of these diseases. Indeed, loss of Lnk 
cooperates with oncogenes, such as JAK2 and BCR-ABL, to induce MPN in mice. These 
animals exhibit a disproportionate expansion of myeloid progenitors and immature precursors 
in vitro and in vivo (Bersenev et al., 2010). Moreover, aged Lnk-/- mice seem to spontaneously 
develop a Chronic Myeloid Leukemia (CML)-like MPN, suggesting a role for Lnk in myeloid 
expansion in vivo. However, this myeloid cell hyperproliferation fails to trigger blast crises, 
reflecting the need of Lnk-deficiency for additional oncogenic events to promote blast 
transformation. Lnk-deficient mice also exhibited an increase in endothelial progenitor cells 
(EPC) numbers that display an enhance capacity for colony formation. Different molecular, 
physiological and morphological approaches have shown that Lnk deficiency promotes 
vasculogenesis/angiogenesis and osteogenesis through the mobilization and recruitment of 
HSCs/EPCs via activation of the SCF/Kit signalling pathway in the ischemic and perifracture 
zone, respectively, thereby establishing an optimal environment for neovascularisation, bone 
healing and remodelling (Kwon et al., 2009, Matsumoto, et al., 2010). Taken together, these 
findings strongly suggest that Lnk regulates bone marrow EPC kinetics during vascular and 
bone regeneration. 
4.3 Cbl-deficient mice 
Mice deficient for c-Cbl and Cbl-b have been invaluable in demonstrating the important roles 
played by these proteins in fine-tuning signalling thresholds in immune cells. Despite close 
structural similarities, loss of c-Cbl and Cbl-b proteins evokes prominent phenotypic 
differences (Table 5). c-Cbl-null mice have an enlarged thymus, expanded hematopoietic 
progenitor pools with increased repopulating capacity, splenomegaly with extramedullary 
hematopoiesis, as well as changes in energy metabolism, and reduced fertility of male mice 
(Murphy et al., 1998; Naramura et al., 1998; Molero et al., 2004; El Chami et al., 2005, Rathinam 
et al., 2008).  However, the most marked alteration in c-Cbl and Cbl-b-deficient animals is being 
associated with thymocyte and peripheral T-cell activation, respectively. c-Cbl-/- mice exhibit 
strong effects on thymocytes, with increase cell numbers in the thymus of the young adult and 
enhanced signal strength following TCR engagement. Moreover, perturbed thymocyte 
signalling does not depend on the TKB domain of c-Cbl, as a TKB knock-in did not rescue the 
phenotype (Thien et al., 2003). In contrast, Cbl-b ablation results in an impaired immunological 
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tolerance induction and animals succumb to spontaneous and/or induced autoimmune 
diseases with widespread inflammatory organ (pancreas, lung) and tissue (adipose) damage 
(Bachmaier et al., 2000, 2007; Hirasaka et al., 2007). Importantly, Cbl-b-null mice are able to 
reject multiple types of tumours spontaneously (Chiang et al., 2007; Loeser et al., 2007). 
The redundant and overlapping functions of Cbl family proteins are more evident from the 
striking phenotypes of Cbl, Cbl-b double-deficient mice. Deletion of both proteins in the 
germline leads to early embryonic lethality (Naramura et al., 2002). In contrast, T-cell 
specific double knock-out mice are viable, however, their T-cells develop independent of 
MHC-restricted thymic selection and these mice eventually succumb to autoimmune-like 
vasculitis early in adult life (Huang et al., 2006; Naramura et al., 2002). Similarly, B-cell 
specific Cbl, Cbl-b double deficiency leads to a failure to acquire tolerance to self antigens 
and the animals developed Systemic Lupus Erythematosus (SLE)-like autoimmune diseases 
(Kitaura et al., 2007). At the molecular level, cells from these double knock-out mice display 
delayed down-modulation of cell surface antigen receptors and prolonged activation of 
downstream signalling pathways. 
Loss of c-Cbl, but not of Cbl-b, led to a significant expansion of HSC and haematopoietic 
progenitors. Strikingly, ablation of both proteins enhanced this phenotype and eventually all 
mice succumbed to aggressive myeloproliferative disease-like leukemia with peripheral organ 
involvement within two to three months after birth (Naramura et al., 2010). Moreover, blastic 
transformation of chronic myelogeneous leukemia in a bcr/abl-transgenic model is accelerated 
in the c-Cbl null background (Sanada et al., 2009). Combined, these observations support that 
c-Cbl can act as a tumor suppressor and that complete loss of Cbl functions is required to 
promote myeloid malignancy. In contrast to the tumor suppressor function of the wild-type c-
Cbl, c-Cbl mutants isolated from human and murine neoplasms, as well as v-Cbl, show clear 
transforming capacity in terms of anchorage-independent growth in soft agar in vitro and 
tumour generation in nude mice in vivo (Sanada et al., 2009; Thien et al., 2001). Bone marrow 
cells transduced with c-Cbl mutants in the linker (70Z) or in the RING finger domain (R420Q) 
generate generalized mastocytosis, a myeloproliferative disease, and myeloid leukemia in 
lethally irradiated mice with long latency but high penetrance (Bandi et al., 2009). The 
transforming activity of these mutant forms of c-Cbl seems to be mediated by alteration of the 
E3 ubiquitin ligase activity. Most c-Cbl mutations in myeloid neoplasms are missense changes 
at highly conserved amino acid positions within the linker and RING finger domains, or 
involve splice-site sequences, leading to amino acid deletions within them. Supporting these 
findings, the generation of knock-in mutants carrying single point mutations in the TKB, linker 
or RING domains of c-Cbl protein has further validated the importance of these domains in 
Cbl-mediated tumorigenesis. Interestingly, mice with an equivalent RING finger domain 
mutation in Cbl-b do not show comparable changes in the haematopoietic compartment, 
indicating that Cbl-b is not capable of inhibiting c-Cbl functions (Rathinam et al., 2010). Taken 
together, mouse models with Cbl family ablation or point mutations have convincingly 
established the role of these proteins as important E3 ubiquitin ligases for the homeostasis of 
the haematopoietic and immune systems and as tumour suppressors. 
4.4 SOCS-deficient mice 
Since the discovery of SOCS proteins, much attention has been drawn to their physiological 
roles and their involvement in human diseases. Many of their common inhibitory activities 
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on cytokine signalling demonstrated in vitro, do not seem to be essential in vivo as genetic 
ablation of CIS, SOCS1, SOCS2 and SOCS3 genes has demonstrated remarkable cytokine 
specificity for different SOCS molecules (Table 5). 
SOCS1-deficient mice are growth retarded and died within 3 weeks of birth with a 
syndrome characterized by severe lymphopenia, activation of peripheral T cells, fatty 
degeneration and necrosis of the liver and multi-organ failure with rampant inflammation 
due to macrophage infiltration of major organs (Alexander et al., 1999; Marine et al., 1999a, 
Starr et al., 1998). The neonatal phenotypes appear primarily as the result of deregulated 
IFN signalling, because SOCS1-/- mice that are also deficient for IFN, do not die neonatally.  
Moreover, constitutive STAT1 activation and IFN-inducible genes were observed in SOCS1 
deficient mice, indicating that IFN signalling is regulated by SOCS1 and that its 
deregulation contributes to the lethal phenotype. However, the SOCS1, IFN double 
deficient mice ultimately died 6 months after birth with inflammation and polycystic 
kidneys, which suggests that SOCS1 regulation is not exclusive to IFN (Metcalf et al., 2002). 
The lethality in SOCS1-/- mice is also significantly delayed in the RAG2-/-, STAT1-/-, STAT6-/- 
and STAT4-/- backgrounds, thus implicating SOCS1 as a critical regulator of IFN, IL-4 and 
IL-12 signalling pathways (Alexander and Hilton, 2004). 
In recent years, it has become clear that some of the SOCS members play critical roles in 
regulating T-cell differentiation, maturation and function by controlling different signalling 
events, as shown by the phenotypes displayed by SOCS1 and SOCS3 deficient mice. In this 
sense, T-cell specific conditional deletion of SOCS1 showed that it is not sufficient to induce 
the lethal multi-organ disease; however it does cause T-cell specific abnormalities that 
include increased numbers of CD8+ T cells and increased sensitivity to cytokines with 
common -chain receptors. SOCS1 also plays an important role in the regulation of Tregs. 
Higher number of Tregs is observed in the thymus and spleen of T-cell-specific SOCS1-
deficient mice (Horino et al., 2008). This is probably due to higher IL-2 responses, because 
IL-2 enhances Tregs proliferation. Moreover, Lu and colleagues have recently showed that 
SOCS1-specific ablation in Tregs induced the development of spontaneous dermatitis, 
splenomegaly and lymphoadenopathy in these mice (Lu et al., 2009). These results point out 
SOCS1 as an important controller of Tregs. 
Analysis of mice bearing the deletion of the SOCS box of SOCS1 demonstrated the in vivo 
importance of the SOCS box for inhibition of IFN signalling by SOCS1. SOCS box deleted-
deficient mice also die prematurely and suffer from reduced body weight. Inflammatory 
lesions are observed in skeletal and heart muscle, cornea, pancreas and dermis.  
SOCS2 is thought to play a major role in the regulation of GH signalling. Indeed, mice 
deficient for SOCS2 develop gigantism with enlargement of visceral organs and 3 months 
after birth weight 30-40% more than control mice, elevated mRNA levels of insulin-like 
growth factor (IGF-1) and enhanced responses to exogenous GH (Metcalf et al., 2000; 
Greenhalgh et al., 2005). Interestingly, over-expression of SOCS2 increases GH signalling 
and SOCS2 transgenic mice develop mild gigantism (Favre et al., 1999). These results 
suggest a more complex role of SOCS2 in regulating GH signalling. To date, there are no 
evidences on the role of SOCS2 in the regulation of immune responses. 
Deletion of SOCS3 leads to embryonic lethality with embryos dying between 12 and 16 days 
of gestation (Marine et al., 1999b). Lethality was initially thought to result from excessive 
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erythropoiesis due to enhanced EPO signalling. However, further studies showed that 
lethality was in fact due to placental insufficiency with poor development of embryonic 
vessels, spongiotrophoblasts, as well as increase in trophoblast giant cell differentiation 
(Roberts et al., 2001). Tetraploid aggregation assays resulting in SOCS3-deficient foetal 
components with SOCS3 sufficient placental tissues, generated live birth SOCS3-/- mice. 
These mice were smaller than littermates, exhibited cardiac hyperthrophy and finally 
succumbed by 25 days. Importantly, SOCS3 lethality could be rescued if mice were also 
deficient for Leukemia-Inhibitory factor (LIF) or its receptor (LIFR), indicating that SOCS3 is 
required for modulating LIF signalling in giant trophoblast cell differentiation (Takahashi et 
al., 2003, Robb et al., 2005). 
SOCS3 has also been shown to play an important role in Th1 and Th2 cell differentiation. 
Indeed, blocking SOCS3 either by a dominant-negative mutant or in heterozygous SOCS3 
mice diminishes the differentiation of Th2 cells, resulting in the skewing of T-cells towards 
the Th1 phenotype and reduced allergic responses (Seki et al., 2003; Kubo et al., 2006). 
Furthermore, over-expression of SOCS3 in T-cells provokes exacerbating Th2 cell-mediated 
eye-allergy, with inhibition of SOCS3 ameliorating the severity of the disease.  
The receptors to which SOCS3 binds mostly activate STAT3, therefore, SOCS3 has been 
considered as a negative regulator of inflammation and an inhibitor relatively specific to 
STAT3. Indeed, mice with a conditional deletion of SOCS3 in haematopoietic and 
endothelial cells die as young adults due to severe inflammatory lesions in the peritoneal 
and pleural cavities (Croker et al., 2004, Robb et al., 2005). If G-CSF is administered to these 
mice, mimicking emergency granulopoiesis during infection, they exhibit massive 
neutrophil infiltration and destruction of liver, lung, muscle and spinal tissue, resulting 
from increased intensity and duration of G-CSF-induced STAT3 activation.  These results 
thus indicate SOCS3 as a negative regulator of G-CSF and STAT3 in myeloid cells. Mice with 
SOCS3-deficient haematopoiesis display also high susceptibility to inflammatory joint 
disease in an IL-1-induced inflammatory model (Wong et al., 2006). Adenoviral gene 
transfer of SOCS3 or dominant negative STAT3 indeed reduced the proliferation of RA 
synovial fibroblasts and the severity of the disease in a mouse model that is also dependent 
on Th17 cells (Shouda et al., 2001). The generation of these same cells is enhanced in T-cell 
specific SOCS3-deficient mice and abrogation of SOCS3 binding site in gp130 knock-in 
mutant mice results in Th17-like arthritis (Taleb et al., 2009; Ogura et al., 2008). Together, 
these results show that the absence of SOCS3 has dramatic pro-inflammatory effects by 
promoting Th17 development and Th17-mediated disease. 
Mice lacking CIS did not display any specific phenotype (Marine et al., 1999a). However, 
CIS-over-expressing transgenic mice recreate a phenotype quite similar to STAT5-deficient 
mice with defects in growth and lactation, GH and prolactin signalling, as well as in natural 
killer, natural killer T-cell and T-cell development (Matsumoto et al., 1999). These results 
support its role in JAK/STAT5 pathway. 
The role of SOCS4 in vivo or in immune responses is to date unknown. However, in vivo 
studies on SOCS5 reveal its possible role in adaptive immunity, notably in Th1 and Th2 cell 
differentiation. SOCS5 transgenic mice show attenuation of IL-4-mediated STAT6 signalling, 
as well as reduced Th2 cell development and production of Th2-type-cytokines (Seki et al., 
2002). Interestingly, SOCS5 over-expression augmented eosinophilic airway inflammation 
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and septic peritonitis in mice (Ohshima et al., 2007; Watanabe et al., 2006). In contrast, 
SOCS5-deficent mice appear to have normal T-cell development and differentiation to both 
Th1 and Th2 cells (Brender et al., 2004). These contradictory phenotypes might be explained 
with the high homology between SOCS4 and SOCS5 denoting a redundant role of these 
proteins in vivo. 
SOCS6-deficient mice do not display overt abnormalities, but just mild growth retardation, 
suggesting its role in cell growth (Krebs et al., 2002). However, SOCS6 over-expression 
results in inhibited insulin signalling and improvement in glucose tolerance, similarly to 
p85-deficient mice (Li et al., 2004). SOCS7 ablation in vivo has mainly delineated its essential 
role in insulin signalling. SOCS7-deficient mice shows multiple defects at an early age with 
half of the homozygous progeny displaying severe hydrocephalus and growth retardation 
concomitant with hypoglycaemia and enhanced glucose metabolism that resulted in 
perinatal lethality (Banks et al., 2005; Krebs et al., 2004). On the other hand, SOCS7 seems to 
have a role in the regulation of allergic inflammatory disease. SOCS7-deficient mice have a 
propensity toward spontaneous development of cutaneous disease with infiltration of 
degranulated mast cells (Knisz et al., 2009). Thus, these studies suggest a role for SOCS7 in 
modulating the development of allergic diseases. 
5. Inhibitory adaptors in human haematological diseases 
As described in the previous section, animal models for the Dok, Lnk, Cbl and SOCS 
families have been invaluable in demonstrating the important roles played by these adaptor 
proteins in fine-tuning signalling thresholds in haematopoietic and immune cells. Some of 
these in vivo models recapitulate exactly or almost, essential features of different 
haematological and immune diseases, allowing us to identify new molecular players and 
mechanisms implicated in the initiation and progression of these malignancies. 
Dok proteins 
Studies on Dok-1 and Dok-2-deficient mice demonstrated that these adaptors are essential to 
suppress the blastic transformation of the Bcr-Abl–induced CML-like disease. However, it is 
of note that in case of patients with CML, blast crisis mostly results in myeloid or B cell 
leukemia/lymphoma, usually not in the T cell variety. That Bcr-Abl mice carrying a p53 
mutation also developed T cell lymphoma suggests involvement of genetic background 
(Honda et al., 2000). Moreover, as double Dok-1/2 knockout mice developed 
myeloproliferative disease in the absence of Bcr-Abl, Dok-1 and Dok-2 may oppose a wide 
range of myeloid leukemogenesis in humans. Consistently, undetectable or marginal levels 
of their expression was observed in about half of the leukemic cell lines established from 
patients with myeloid leukaemia, regardless of whether it is CML or not (Yasuda et al., 
2004). Further investigation of the tumour suppressive function of Dok-1 and Dok-2 in 
human malignancies, especially myeloid leukaemia including CML and CMMoL, might 
lead to an understanding of the molecular mechanisms of such diseases and contribute to 
designing effective therapies against them (Table 5). 
Histiocytic sarcoma (HS) is a malignant proliferation of cells showing morphological and 
immunophenotypic features of mature histiocytes, which represent tissue-resident 
macrophages. Until recently, HS, which was also known as malignant histiocytosis, was 
often confused with anaplastic large B-cell lymphoma or with other malignant lymphomas 
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(Weiss et al., 2009). As the molecular etiology of this disease is unknown, there remains a 
need for realistic animal models. Mouse models that have been reported for HS frequently 
show multiple lesions including lymphomas and severe renal failure. The syndrome elicited 
in mice lacking all the three proteins, Dok-1, Dok-2, and Dok-3, more specifically resembles 
the disease found in humans and hence may serve as a useful model for the study of HS. 
Although elucidation of the mechanisms by which the ablation of Dok proteins specifically 
causes HS and how the tumour gains its aggressive phenotype awaits further studies, such 
studies will help unveil the hidden etiology of this rare aggressive human malignancy. 
Lnk proteins 
Lnk-deficient mice display a phenotype reminiscent of BCR-ABL negative (Ph-) MPNs, 
notably Essential Thrombocythemia (ET) and Primary Myelofibrosis (PMF) that has 
suggested a role for Lnk in the development of these diseases (Table 5). All MPNs are clonal 
disorders of HSC characterized by excessive proliferation of haematopoietic cells due to 
hypersensibility to normal cytokine regulation and absence of negative feed back regulation. 
The recent discovery of the Val617Phe acquired mutation of the JAK2 gene (JAK2-V617F) 
represents the first reliable molecular marker of Ph- MPN (Campbell & Green, 2008). The 
pathogenic role of JAK2-V617F constitutive active kinase and more recently of mutated Mpl 
(MPLW-515L) most likely will go through abnormal activation of signalling molecules, 
among which Lnk likely plays an important negative regulatory role through its binding to 
JAK2-V617F and MPL-W515L forms. Indeed, recent work has demonstrated a modulation of 
Lnk level in megakaryocyte/platelets and CD34+ cells from MPNs patients (Baran-Marszak 
et al., 2010). Recently, the first LNK mutations in JAK2-V617F-negative MPN patients (ET 
and PMF) were identified (Oh et al., 2010).  Both mutations are on exon 2, one (E208Q) is a 
missense mutation in the PH domain (ET patient), while the second mutation lead to a 
premature stop codon resulting in the absence of the protein (PMF patient). The prevalence 
of such mutations is rare (5% or less). However, other LNK mutations  have been identified 
in leukemic transformation of MNP at a higher frequency [13%] (Pardani et al., 2010). 
Moreover, LNK exon 2 mutations were also found in pure erythrocytosis (Lasho et al., 2010). 
In this case, one mutation (A215V) was previously described in PMF blast crisis and another 
(E208X) results in absence of the protein. This finding suggests that the LNK mutations 
induce an MPN phenotype that may depend on different parameters, such as the presence 
of other mutations (Lasho et al., 2011).  
Genome-wide association studies (GWAS) have recently revealed that different diseases share 
susceptibility variants. The LNK/SH2B3 gene maps on chromosome 12q24 and a non-
synonymous single nucleotide polymorphisms (SNP) in this gene has been reported in exon 2 
resulting in a missense mutation at position 262 leading to a R262W amino acid substitution in 
the PH domain. Surprisingly, this nsSNP has recently been associated with inflammatory 
disorders, such as celiac disease (Hunt et al., 2008; Zhernakova et al., 2010), type 1 diabetes 
(Lavrikova et al., 2010), asthma (Gudbjartsson et al., 2009) multiple sclerosis (Alcina et al., 
2010), and also to eight clinically relevant haematological parameters (Soranzo et al., 2009; 
Ganesh et al., 2009) in different populations. Furthermore, the LNK R262W variant has also 
been associated to cardiovascular diseases such as myocardial infarction, coronary heart 
disease and hypertension (Gudbjartsson et al., 2009; Ikram et al., 2010). All these data suggests 
that Lnk nsSNP could be a risk variant for these diseases contributing to their pathogenesis, 
and in consequence, providing a useful diagnostic marker. 
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Animal models have demonstrated the enhanced biological responses in the haematopoietic 
and immune system of Cbl family members when they are either genetically ablated or 
point mutated. It is in this context that the recent identification of mutations in CBL in 
patients with myeloid malignancies provides an important milestone (Table 5). Two groups 
simultaneously identified CBL mutations in Acute Myeloid Leukaemia (AML) patient 
samples (Sargin et al., 2007; Caligiuri et al., 2007). CBL mutations are most frequently 
observed in a distinct group of myeloid disorders named myelodysplastic 
syndromes/myeloproliferative neoplasms (MDS/MPN) that include: the Chronic 
Myelomonocytic Leukaemia (CMML), atypical Chronic Myeloid Leukaemia (aCML) and 
Juvenile Myelomonocytic Leukaemia (JMML). They originate from immature 
haematopoietic progenitors and are characterized by the production of dysplastic blood 
cells and myeloproliferative features. In most adult cases, mutations seem to be somatic, but 
germline mutations were reported in some JMML cases in children (Loh et al., 2009; 
Niemeyer et al., 2010; Martinelli et al., 2010). Genetic alterations in these haematological 
malignancies are strongly associated with hyperactivation of the Ras/MAPK signalling 
pathway due to activating mutations in signalling molecules involved in this pathway 
accounting for approximately 75%cases of JMML (Schubbert, et al., 2007). Strikingly, CBL 
mutations are found in 5% of aCML and up to 15% of JMML and CMML (Grand et al., 2009; 
Loh et al., 2009; Muramatsu et al., 2010; Shiba et al., 2010; Dunbar et al., 2008; Sanada et al., 
2009). Most CBL mutations associated with myeloid malignancies are clustered around the 
linker and the RING finger domains and in vitro studies with these mutants have shown 
their lack of E3 ubiquitin ligase activity (Sargin et al., 2007; Grand et al., 2009; Sanada et al., 
2009). Complete loss of CBL, deletions or mutations outside the linker/RING finger domains 
are rare, as well as mutations in CBLB. These findings suggest that expression of mutant Cbl 
proteins act as dominant negative inhibitor of wild-type Cbl or even of lost Cbl expression. 
A remarkable genetic feature of c-CBL mutations in these myeloid neoplasms is that 
mutations are homozygous in most cases, as a result of duplication of the mutated parental 
copy of 11q (where the CBL gene resides) and loss of the remaining wild-type allele, a 
genetic process called “acquired uniparental disomy” (aUPD) (Grand et al., 2009). This 
feature underlies the gain-of-function nature, rather than a loss-of-function, of the CBL 
mutations and may represent a defining oncogenic event.  Indeed, mutations involving 
RUNX1, JAK2, FLT3 and TP53 have been shown to coexist with CBL mutations in myeloid 
neoplasms (Sanada et al., 2009; Perez et al., 2010; Tefferi, 2010; Makishima et al., 2011) 
suggesting that additional oncogenic events may contribute to the mutant Cbl-driven 
leukemogenic process. 
SOCS proteins 
There is now emerging evidence that SOCS expression is differentially regulated during Th 
cell differentiation and in Th-driven inflammatory diseases (Table 5). In Th1 inflammatory 
diseases (rheumatoid arthritis, ulcerative colitis, Crohn disease, contact and atopic 
dermatitis), SOCS1 expression is observed in  lymphocytes and macrophages, as well as 
keratinocytes and stromal cells that are capable of antigen presentation, but granulocytes are 
negative (Egan et al., 2003; Federici et al., 2002). Importantly, SOCS3 expression levels seem 
to correlate with the severity of this type of inflammatory diseases (Seki et al., 2003; Shouda 
et al., 2001; Suzuki et al., 2001). The same is true for Th2-driven asthma that promotes 
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lymphocyte, basophile and mast cell infiltration, where SOCS3 expression in Th2 
lymphocytes is elevated. Furthermore, the association of the function of SOCS molecules in 
the allergic response has been supported by human studies analyzing the association of 
polymorphisms in SOCS genes with allergic disease in people. Interestingly, an association 
of a promoter polymorphism leads to a promoter with modified activity in vitro, suggesting 
that changes in SOCS1 expression can have considerable effects on disease manifestations in 
patients (Harada et al., 2007). SOCS1 expression has been found decreased in some human 
cancers including hepatocellular carcinoma and myeloproliferative neoplasms and this is 
frequently associated with hyper-methylation of one or more SOCS genes (Yoshikawa et al., 
2001; Watanabe et al., 2004; Quentmeier et al., 2008; Chaligné et al., 2009). In some cases, this 
methylation has been correlated to the degree of malignancy (Okochi et al., 2003; Yoshida et 
al., 2004). These observations strongly suggest that SOCS proteins may be tumour 
suppressors. Loss of SOCS expression may then contribute or favour tumour progression in 
synergy with other oncogenes. SOCS expression has also been implicated in the resistance to 
interferon in haematopoietic malignancies, such as leukaemia, lymphomas and multiple 
myeloma (Sakamoto et al., 2000, Sakai et al., 2002). Persistent expression of SOCS1 and/or 
SOCS3 has been detected in cutaneous T-cell lymphoma (CTCL), chronic myeloid leukaemia 
(CML), and some acute leukaemia (Brender et al., 2001b; Cho-Vega et al., 2004; Roman-
Gomez et al., 2004). In these circumstances, elevated expression of SOCS coincides with 
constitutive activation of JAK/STAT pathways. Moreover, in certain myeloproliferative 
neoplasm, SOCS3 has been found hyper-phosphorylated, which enhances the half-life of the 
protein but interferes with its regulatory function (Hookham et al., 2007; Elliott et al., 2009; 
Suessmuth et al., 2009). These data suggests that perturbed SOCS expression may contribute 
to the malignant phenotype and favour disease progression, rather than being an early 
event in the oncogenic process. 
6. Therapeutic application of inhibitory adaptors 
Given the central role played by inhibitory adaptors in the regulation of different aspects of 
haematopoietic and immune cell function, they are predicted to serve as excellent new 
targets in the development of anti-oncogenic, anti-inflammatory and immunosuppressor 
reagents. The advantage of these adaptors as targets is their restricted expression in cells of 
the haematopoietic and immune system, at least of some of the members in the different 
families discussed here. The disadvantage for some of them (Dok, Lnk) is their lack of 
enzymatic activity for drug targeting. However, this can be surpassed by utilizing strategies 
based in the direct inhibition or blockade of their specific protein-protein interactions for 
targeting a particular signalling pathway. This approach relies on the current information 
available on the molecular structure of the adaptor functional domains and the 
identification of specific sequences or residues involved in the adaptor/partner interaction. 
In some pathological contexts, the association of the inhibitory adaptor with mutated or 
oncogenic forms of its targets is modified from that engaged with its normal counterpart 
(Baran-Marszak et al., 2010). These findings open the possibility to use the binding sequence 
in the adaptor to exclusively inhibit the oncogenic protein and signalling pathway, while 
sparing the normal cell signalling cascades. Indeed, successful development of small 
molecule inhibitors of protein-protein interaction has begun to emerge, validating it as a 
practical approach (Azmi & Mohammad, 2009). The use of dominant negative forms of 
these inhibitory proteins has also proved to be advantageous, notably for adaptors that have 
www.intechopen.com
 
Negative Regulation of Haematopoiesis: Role of Inhibitory Adaptors 
 
79 
shown dual functions, as positive and negative regulators, as they allow modulate 
specifically their function depending on the cell type and biological response to be 
addressed. In the case of Lnk, its loss or inhibition causes the abnormal expansion and 
enhanced ability for engraftment of HSC (Takizawa et al., 2006); this feature can be used for 
bone marrow transplantation where the scarce number of these cells is always the limiting 
factor for the use of this therapy. 
On the other hand, adaptors with catalytic activity, like the Cbl and SOCS proteins, have the 
double advantage of being used as adaptors and as E3 ligase. In the case of Cbl, it is clear 
that its ligase activity is central to the regulation of many oncogenic proteins, so drugs that 
could enhance this activity may provide new therapeutic strategies for limiting their 
constitutive signalling. A potential strategy is the screening for molecules that could mimic 
the activation of its E3 activity while retaining its targets binding. This can be use in 
basophile and mast cells of allergic patients as a therapy to treat allergy diseases. In the case 
of SOCS, a strategy based in the delivery of the SOCS3 protein using a recombinant cell 
penetrating moiety has proved to increase the concentration and activity of SOCS3 in the 
cells and suppressed the effects of acute inflammation (Jo et al., 2005).  Moreover, 
therapeutic trials using SOCS antisense oligonucleotide, small hairpin RNA and peptide 
mimetics are currently investigated in animal models (Yoshimura et al., 2007). Importantly, 
a better understanding of the spectrum of signalling alterations provoked by mutant forms 
of the inhibitory adaptors identified in human pathologies is likely to reveal therapeutic 
strategies for patients with these mutations. In this context, the association of single 
nucleotide polymorphisms (SNP) in the genes of some of these adaptors (LNK, SOCS) with 
different inflammatory, myeloproliferative and vascular diseases suggests the implication of 
these molecules as risk factor and their potential use as biomarkers in these diseases. Lastly, 
future challenges in the study of inhibitory adaptors lie also in the development of 
performing techniques that will allow accurate monitoring of their signalling complexes at 
the molecular level. Indeed, precise regulation of protein interactions is of medical 
relevance, as modifications in the composition or localization of crucial components of these 
signalling networks can lead to the development of human diseases. 
7. Conclusions 
Over the past decade, it has become clear the pivotal role that cytokines play in the 
development and pathology of human diseases, including those of the haematopoietic and 
immune system. They perform their actions by regulating essential biological functions, 
such as cell proliferation, differentiation, cell morphology and migration. It is therefore not 
surprising that cytokine signal transduction pathways are tightly regulated. To achieve this, 
they have set up a variety of mechanisms and the rate at which the signal is turned off will 
be due to the net effect of all of these regulatory pathways. Although initially identified and 
best understood as mediators of positive signalling, adaptors have also shown an equally 
critical role in the negative control of signalling events. Inhibitory adaptors have been 
demonstrated important for maintaining homeostasis by preventing inappropriate cellular 
activation (Lnk, Cbl), by localizing enzymatically active regulatory molecules to specific 
subcellular compartments (Dok), and/or by terminating signalling cascades once they are 
initiated through targeting activated mediators to degradative pathways (Cbl, SOCS). In 
doing so, these molecules act upon three key signalling intermediates (the receptor, 
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JAK/other kinases, and STATs/downstream effectors) to completely switch off the signal. 
In contrast to SOCS and Lnk, which are induced in response to cytokines, Cbl and Dok (with 
the exception of Dok-2 in some cases) are constitutively present in the cell and may therefore 
function as more acute, early response regulators. The timing and specificity of each of these 
mechanisms, as well as how the inhibitors interact and cooperate with each other, is still an 
area for future investigation. Furthermore, the fact that the expression of these adaptors is 
itself regulated, points out further the complexity of the regulatory system. While gene-
targeting studies have highlighted critical roles for the inhibitory adaptors in immune 
function, haematological malignancy and inflammation, the complexity of the mouse 
models, particularly with regard to multi-gene families, suggests that these studies should 
be carefully interpreted, and certainly more work is required before we can predict the 
consequences of using these molecules or their agonists/antagonists in a clinical setting. 
Thus, one of the challenges for the future is sorting out the roles of negative regulators of 
cytokine signalling in all the existing pathways activated in response to cytokines. This 
knowledge is likely to yield both new and confirmatory findings, with the anticipation of a 
better understanding of how these adaptors orchestrate the functional activity and fate of 
many partners to produce the desired intensity of a signalling response. Although a great 
deal of research remains to be done to clarify the roles of these inhibitors and their mutant 
forms in human diseases such as cancer and inflammation, it can be foreseen that it will lead 
to the development of strategies based on the up- or down-regulation of their properties for 
therapeutic purposes. 
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